Wireless Communications System Integrating Electronics Into Orally Ingestible Products For Controlled Release Of Active Ingredients

ABSTRACT

Various embodiments of the present disclosure include a consumable capsule containing an active ingredient in at least one compartment movably sealed by a stimuli responsive actuator, and an activation device configured to communicate with the consumable capsule. The activation device is configured to emit a wireless signal to activate the stimuli responsive actuator of the consumable capsule, and the consumable capsule is configured to release the active ingredient into an external environment based on the activation of the stimuli responsive actuator.

CROSS-REFERENCE

The present application is a Continuation of U.S. patent applicationSer. No. 14/946,478, filed Nov. 19, 2015, entitled “WIRELESSCOMMUNICATIONS SYSTEM INTEGRATING ELECTRONICS INTO ORALLY INGESTIBLEPRODUCTS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS,” which claimspriority to U.S. Provisional Patent Application No. 62/081,988, filedNov. 19, 2014; U.S. Provisional Patent Application No. 62/134,839, filedMar. 18, 2015; and U.S. Provisional Patent Application No. 62/191,149,filed Jul. 10, 2015, each of which is incorporated herein as if set outin full.

BACKGROUND

Individuals in need of active ingredients for a desired biologicalresponse are generally required to ingest the active ingredients aroundthe time at which the biological response is desired. For example, anathlete participating in a sporting event may require rehydration atsome point during the event, and such rehydration can generally only beaccomplished by consuming during the event a product that includes anactive ingredient that can aid in rehydration (e.g., electrolytes). Inmany instances, the need to consume active ingredients during an eventcan be a competitive disadvantage, such as in situations where theathlete needs to physically slow down or completely stop in order toconsume the desired active ingredient.

U.S. Pat. Nos. 8,449,920, 8,518,448, and 8,545,892 describesustained-released beads that can be included in consumable products,such as foods or beverages. The sustained-released beads are consumedat, e.g., the beginning of an athletic event, and are designed todeliver an active ingredient over an extended period of time. In thismanner, an athlete can consume an active ingredient once (e.g., beforean athletic event begins) but still be provided with the activeingredient over the course of the event and without having to slow downor stop participation in the athletic event in order to consumeadditional active ingredient(s).

While useful in athletic competitions, the above-describedsustained-release beads are not capable of providing precision,on-demand delivery of active ingredients. For example, if an athlete isparticipating in a bicycle race and desires a burst of caffeine as he orshe approaches a steep climb, the athlete has no way to make thepreviously ingested sustained-release beads provide the activeingredient at the exact time the athlete begins his or her climb.Generally speaking, the rate at which the active ingredient is deliveredto the athlete is outside of the athlete's control once the product isconsumed. The sustained release beads can be designed to provide activeingredients at general time intervals, but various factors (e.g., theathlete's own physiology) will alter the timing at which the activeingredient is released, thereby making precision, on-demand delivery ofan active ingredient during an event exceedingly difficult, if notimpossible, to achieve.

SUMMARY

The present disclosure is directed to a system including a consumableitem, such as a capsule, having internal electronic components disposedtherein that can be used to provide on demand delivery of an activeingredient also included within the consumable capsule. In someembodiments, the consumable capsule will be in the form of a bead,capsule, tablet, or the like, and will include one or more activeingredients and internal electronic components that are capable ofwirelessly receiving electrical power and/or command signals from anexternal communication device or activation device that is also part ofthe system. When a signal is sent from the external communication deviceor activation device to the internal electronic components, a releaseaction is initiated which results in the consumable capsule releasingthe active ingredient. In this manner, on demand delivery of activeingredients to the consumer of the consumable capsule is possible.

Methods of and materials for making the consumable capsule describedherein are also disclosed.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 diagrammatically represents an embodiment of a consumable capsuleincluding active ingredients and internal electronic componentsaccording to some embodiments described herein.

FIG. 2 diagrammatically represents an embodiment of a system in which anexternal communication device communicates with a consumable capsuleingested by a consumer to thereby release the active ingredient in theconsumable capsule into the consumer's GI tract.

FIG. 3 diagrammatically represents an embodiment of a system in which anexternal communication device communicates with an activation device torelease an active ingredient in a consumable capsule into the consumer'sGI tract.

FIG. 4A diagrammatically represents an embodiment of a system in whichan activation device (such as one incorporated into a wearable item)communicates with a consumable capsule ingested by a consumer to therebyrelease the active ingredient in the consumable capsule into theconsumer's GI tract.

FIG. 4B diagrammatically represents an embodiment of a system in whichan external communication device communicates with both an activationdevice (such as one incorporated into a wearable item) and a consumablecapsule ingested by a consumer to thereby release the active ingredientin the consumable capsule into the consumer's GI tract.

FIG. 5A diagrammatically represents another embodiment of a system inwhich an activation device (such as one incorporated into a wearableitem) communicates with a consumable capsule ingested by a consumer tothereby release the active ingredient in the consumable capsule into theconsumer's GI tract.

FIG. 5B diagrammatically represents another embodiment of a system inwhich an external communication device communicates with activationdevice (such as one incorporated into a wearable item) to release anactive ingredient in a consumable capsule into the consumer's GI tract.

FIG. 6A diagrammatically represents an embodiment of a system forpowering and triggering a consumable capsule.

FIG. 6B diagrammatically represents an embodiment of the consumablecapsule power management circuitry.

FIG. 6C diagrammatically represents an alternative embodiment of theelectronics within the consumable capsule.

FIGS. 7A-7C illustrate an example of an embodiment of a consumablecapsule, in accordance with various aspects of the present disclosure.

FIGS. 7D-7F illustrate an example of an alternative embodiment of aconsumable capsule, in accordance with various aspects of the presentdisclosure.

FIGS. 8A-8C illustrate an example of an embodiment of the consumablecapsule shown in FIGS. 7A-7C after the delivery compartments are opened,in accordance with various aspects of the present disclosure.

FIGS. 8D-8F illustrate an example of an alternative embodiment of theconsumable capsule shown in FIGS. 7D-7F after the delivery compartmentsare opened, in accordance with various aspects of the presentdisclosure.

FIGS. 9A-9C illustrate an example of another embodiment of a consumablecapsule, in accordance with various aspects of the present disclosure.

FIGS. 9D-9F illustrate an example of an alternative embodiment of aconsumable capsule, in accordance with various aspects of the presentdisclosure.

FIGS. 10A-10C illustrate an example of an embodiment of the consumablecapsule shown in FIGS. 9A-9C after the delivery compartments are opened,in accordance with various aspects of the present disclosure.

FIGS. 10D-10F illustrate an example of an alternative embodiment of theconsumable capsule shown in FIGS. 9D-9F after the delivery compartmentsare opened, in accordance with various aspects of the presentdisclosure.

FIGS. 11A-11C illustrate an example of still another embodiment of aconsumable capsule, in accordance with various aspects of the presentdisclosure.

FIGS. 12A-12C illustrate an example of an embodiment of the consumablecapsule shown in FIGS. 11A-11C after the delivery compartments areopened, in accordance with various aspects of the present disclosure.

FIGS. 13A-13B illustrate an example of yet another embodiment of aconsumable capsule, in accordance with various aspects of the presentdisclosure.

FIGS. 14A-14B illustrate an example of an embodiment of the consumablecapsule shown in FIGS. 13A-13C after the delivery compartment is opened,in accordance with various aspects of the present disclosure.

FIG. 15 is a flowchart illustrating an example of a set of operationsfor triggering the release of active ingredients, in accordance withvarious aspects of the present disclosure.

FIG. 16 is an example of an embodiment of a computer system with whichembodiments of the present technology may be utilized.

DETAILED DESCRIPTION

Embodiments described herein are generally directed to orally ingestibledelivery systems including internal electronic components (e.g., areceiver) and one or more active ingredients incorporated into aconsumable item such as a capsule, wherein all of the components of theconsumable capsule are safe for consumption by a mammal, such as ahuman. Another component of the system can include activation device(such as one incorporated into a wearable item) or an externalcommunication device that is used by the consumer to communicate withthe internal electronic components in the consumable capsule afterconsumption of the consumable capsule.

The consumable capsule can be provided in any form generally suitablefor consumption by a user and which is capable of housing the internalelectronic components. In some embodiments, the consumable capsule is inthe form of a product that can be swallowed by a consumer without havingto chew or break up the consumable capsule prior to being swallowed.Providing a consumable capsule that can be swallowed whole protects theinternal electronic components included in the consumable capsule. Insome embodiments, the consumable matrix may be in the form of a capsule,tablet, pill, or bead (e.g., a microbead). In some embodiments, theconsumable capsule may be dispersed within a food or beverage andprovided with a coating or other barrier that prevents the consumablecapsule from breaking down while stored in the food or beverage.

The consumable capsule generally includes two primary components: theinternal electronic components that allow the consumable capsule toreceive signals and/or power from an external communication device oractivation device, and one or more active ingredients. Other componentsthat can be included in the consumable capsule will also be discussed.

FIG. 1 diagrammatically represents a consumable capsule 100 according tosome embodiments described herein. The consumable capsule 100 includesinternal electronic components 110 and active ingredients 120. Theconsumable capsule 100 can also include an optional coating layer 130.As shown in FIG. 1, the active ingredients 120 generally surround theinternal electronic components 110, although other orientations arepossible. The active ingredients 120 can also be mixed with othermaterial (e.g., binding agent) to form the material surrounding theinternal electronic components 110.

The internal electronic components included in the consumable capsulecan be any electronic components that are safe for consumption. In someembodiments, the internal electronic components include at least areceiver capable of receiving a signal from an external communicationdevice or activation device. In order to be safe for consumption, theinternal electronic components should not include any material that istoxic to the consumer or that is included in an amount that is toxic toa consumer. In some embodiments, the internal electronic components areelectronic components that have been approved for consumption by theU.S. Food and Drug Administration. The electronic components may bedigestible, or may be designed to pass through the consumer.

In some embodiments, the electronic components may include one or moremicrocontrollers, microprocessors, and/or radio frequency identification(RFID) receiver capable of passing safely through the body. In someembodiments, the microcontrollers/microprocessors/RFID receiver includematerials such as silicon, magnesium, and copper, each of which isincluded in an amount that is not dangerous to a human consuming themicrochip.

The electronic components may be capable of functioning to aid inaccomplishing at least two primary objectives. First, the electroniccomponents can function with the receiver to receive signals from anexternal communication device or activation device. In some embodiments,the electronic components function with an internal receiver only toreceive a signal from one or more external transmitters (one waycommunication), while in other embodiments, the electronic componentsfunction together with an internal transmitter to both receive andtransmit signals to and from one or more external transceivers (two waycommunication). Second, the electronic components can function to carryout or aid in carrying out the release activity that results in activeingredients being released from the consumable capsule and being madeavailable to the consumer's GI tract. In some embodiments, the releaseactivity carried out using the electronic components is carried out uponreceipt of a signal from the external transmitter.

The electronic components may include memory sufficient to store aprogramming instructions that, when executed, allows the consumablecapsule to receive and/or transmit signals (via interaction/associationwith an internal transceiver) and/or initiate and carry out a releaseactivity (via interaction/association with components included in theconsumable capsule to perform a release activity).

The ability of the electronic components to function with the internaltransceiver to send and/or receive signals can be accomplished using anysuitable wireless communication means. In some embodiments, theelectronic components are designed to allow for communication betweentransmitters and receivers via RF signals, although other types ofwireless communications are contemplated, such as RFID communications,Bluetooth communications, near field communications (NFC), opticalcommunications, or the like. In some embodiments, the electroniccomponents may be designed to allow for communication in sub 1 GHzIndustrial-Scientific-Medical (ISM) frequency bands, such as 125 Khz, 1Mhz, 13.56 Mhz, 433 Mhz, and 915 Mhz. Lower frequency bands may havebetter penetration of the body. In other embodiments, the electroniccomponents may be designed to allow for communication using frequenciesthat are common to cellular devices, such that the externalcommunication device may be a cellular device. Suitable frequenciesinclude UMTS/HSDPA/HSUPA (850, 900, 1900, 2100 MHz), GSM/EDGE (850, 900,1800, 1900 MHz), 2.4 GHz ISM (Channels 1-11), 5 GHz UNII-1 (Channels36-48), 5 GHz UNII-2 (Channels 52-64), 5 GHz-2Ext (Channels 100-140),and 5 GHz UNII-3 (Channels 149-161).

The internal electronic components of the consumable capsule are capableof communicating with any variety of external communication device oractivation device using the same communications protocol as the internalelectronic components. In some embodiments, the external communicationdevice may be a cellular device (e.g., cellular phone), a tabletcomputer, a personal digital assistant (PDA), a Bluetooth device, aGlobal Positioning Satellite (GPS) device, or the like.

The external communication device or activation device may includeprogrammable software and a user interface that allows the user toinitiate a signal to the consumable capsule. For example, when theexternal communication device is a smartphone, the smartphone may runappropriate software (such as via an app) that provides a user interfacefor initiating a signal to the consumable capsule.

FIG. 2 diagrammatically represents an embodiment of a system in which anexternal communication device 210 communicates with a consumable capsule220 ingested by a consumer 200. As shown in FIG. 2, the consumablecapsule 220 is located in the consumer's GI tract 201, specifically theconsumer's stomach, after being ingested by the consumer 200. Theconsumable capsule 220 is capable of residing in the consumer's GI tract201 for a period of time during which the consumable capsule 220significantly does not break down. An external communication device 210is used to transmit a signal (or signals) 211 to the consumable capsule220, and more specifically, to the internal electronic components (notshown) included within the consumable capsule 220. When the signal 211is received by the consumable capsule 220, a release activity isinitiated and carried out by the internal electronic components, whichresults in the release of the active ingredient included in theconsumable capsule 220 into the consumer's GI tract 201. In someembodiments, the signal 211 may also provide power to the consumablecapsule 220 to enable the release of the active ingredient. In aparticular embodiment, the active ingredient is prevented from beingreleased until the signal 211 is received by the consumable capsule 220,thereby allowing the consumer 200 to use the external communicationdevice 210 to dictate more precisely when the active ingredient is madeavailable for uptake by the consumer's GI tract.

In some embodiments, a secondary transceiver can be a part of the systemincluding the external communication device and the internal electroniccomponents of the consumable capsule. The secondary transceiver may beused as an intermediate communications relay between the internalelectronic components and the external communication device, and mayinclude additional and/or more versatile electronic components thatrelay messages between the internal electronic components and theexternal communication device. In one example, the secondary transceiveris provided primarily as a way to receive a signal from the externalcommunication device, optionally process the signal information in someway, and relay the information to the consumable capsule. The secondarytransceiver may solve the issue of the internal electronic components inthe consumable capsule only being capable of sending or receivingcertain types of information small distances due to the size andrelative simplicity of the internal electronic components.

The secondary transceiver may be included within an activation devicethat is worn somewhere on the body of the user (i.e., a wearable item)so as to always stay relatively close to the consumable capsule. In someembodiments, the activation device is a patch or belt worn on the body.The size of the secondary transceiver within the activation device isgenerally substantially larger than the internal electronic componentsof the consumable capsule and can therefore include a more complexsystem that is capable of carrying out more functions than the internalelectronic components in the consumable capsule. In one specificexample, the secondary transceiver is capable of relaying a signalacross a larger distance than is possible with the internal electroniccomponents of the consumable capsule, which thereby allows the externalcommunication device to be farther away from the user while stillallowing for communication between the external communication device,the secondary transceiver, and the consumable capsule.

FIG. 3 diagrammatically represents an embodiment of a system using thesecondary transceiver within an activation device described above. Asshown in FIG. 3, the consumable capsule 220 is located in the consumer'sGI tract 201 after being ingested by the consumer 200. The consumablecapsule 220 is capable of residing in the consumer's GI tract 201 for aperiod of time during which the consumable capsule 220 does notsignificantly break down. An external communication device 210 is usedto transmit a signal (or signals) 211 to activation device 240positioned somewhere externally on the consumer's body. A secondarytransceiver within the activation device 240 receives signal 211 andtransmits a relay signal 212 to the consumable capsule 220, and morespecifically, to the internal electronic components (not shown) includedwithin the consumable capsule 220. When the relay signal 212 is receivedby the consumable capsule 220, a release activity is initiated andcarried out, which results in the release of the active ingredientincluded in the consumable capsule 220 into the consumer's GI tract 201.In some embodiments, the signal 212 may also provide power to theconsumable capsule 220 to enable the release of the active ingredient.In a particular embodiment, the active ingredient is prevented fromreleasing until the relay signal 212 is received by the consumablecapsule 220, thereby allowing the consumer 200 to use the externalcommunication device 210 and the secondary transceiver within theactivation device 240 to dictate exactly when the active ingredientshould be made available for uptake by the consumer's GI tract. Thesecondary transceiver can receive signals 211 from the externalcommunication device 210 from a distance further away than if theexternal communication device 210 communicated directly with theconsumable capsule 220.

As noted above, the system can be designed for one way or two waycommunication. In a one way communication system, the externalcommunication device 210 is used exclusively to transmit signals to theactivation device 240 and does not receive any information back from theconsumable capsule 220 or activation device 240. Similarly, the internalelectronic components in the consumable capsule 220 may be designed toonly receive signals from the activation device 240. In otherembodiments, each component of the system can send and receiveinformation, allowing for a more diverse range of operations. In oneexample, where two way communication is provided, the internalelectronic components or the consumable capsule 220 provide a signal tothe external communication device 210 or activation device 240 includinginformation relating to the state of the consumable capsule 220, e.g.,whether the consumable capsule has released the active ingredient.

In some embodiments, the systems described above and illustrated inFIGS. 2 and 3 can be used in conjunction with an activation device 240that is capable of monitoring one or more aspects of a user's health. Insuch embodiments, the activation device 240 monitors a user's health andnotes when a condition arises requiring potential administration of anactive ingredient. When such a condition arises and is noted by theactivation device, the activation device can transmit a signal eitherdirectly to the consumable capsule to initiate the release of an activeingredient, or to the external communication device 210 such that theuser or a person remotely monitoring the external communication device210 can initiate the release of an active ingredient. The incorporationof an activation device 240 that is capable of health monitoring intothe systems described herein can help to ensure the more accurate andtimely release of active ingredients into a user's system.

In some embodiments, the external communication device 210 and/oractivation device 240 may detect environment conditions and/or movement.For example, the external communication device 210 and/or activationdevice 240 may detect elevation, air temperature, movement speed, orother characteristics of the consumer 200 or consumer's environment.Based on this detection, the external communication device 210 and/oractivation device 240 may automatically trigger the consumable capsule220 to release an active ingredient. For example, the externalcommunication device 210 and/or activation device 240 may automaticallytrigger the release of an active ingredient when the consumer 200 passesa certain elevation, or when the air temperature drops below a certainlevel, or when the consumer 200 is moving above a certain speed. Theconditions for automatically releasing the active ingredient may be setby the consumer 200. In some embodiments where a smartphone is used asthe external communication device 210, the consumer 200 may set theconditions for automatically releasing the active ingredient using anapplication stored on external communication device 210.

With reference to FIG. 4A, a diagrammatic representation of anembodiment of a system in which the consumer 200 wears activation device400 is shown. The activation device 400 may be used to monitor one ormore aspects of the consumer's health. As shown in FIG. 4A, theactivation device 400 is a wearable item that is worn on the consumer'sarm, but the location of the activation device 400 on the consumer 200is generally not limited. Similarly, the aspect of the consumer's healththat is monitored by the activation device 400 is also not limited.

When the activation device 400 monitors a condition in the consumer'shealth requiring an active ingredient, a signal (or signals) 411 may besent directly to the consumable capsule 220 already ingested by theconsumer 200. Receipt of the signal 411 triggers the consumable capsule220 to carry out an event that results in the release of activeingredient into the consumer's GI tract 201. In some embodiments, thesignal 411 may also provide power to the consumable capsule 220 toenable the release of the active ingredient. In this manner, the systemshown in FIG. 4 is well suited for timely and accurate release of activeingredients based on the specific response to a monitored health event.

When the activation device 400 sends a signal 411 directly to theconsumable capsule 220, the activation device may incorporate some orall of the technology typically included in the external communicationdevice 210 discussed above. As a result, in some embodiments, theactivation device 400 may eliminate the need for an externalcommunication device 210.

With reference to FIG. 4B, a diagrammatic representation of anembodiment of a system in which the consumer 200 is again wearingactivation device 400 is shown. However, in the embodiment illustratedin FIG. 4B, a signal (or signals) 412 is sent from the activation device400 to the external communication device 210, which is then used to senda signal (or signals) 413 to the consumable capsule 220 and trigger theevent that releases active ingredient into the GI tract of the consumer200. In some embodiments, the signal 413 may also provide power to theconsumable capsule 220 to enable the release of the active ingredient.As in FIG. 4A, the signal 412 is initiated when the activation device400 measures a condition in the consumer's 200 health requiring anactive ingredient. The signal 412 is received by the externalcommunication device 210, which can then produce an alert describing thehealth event measured by the activation device 400. Either the consumer200 or a person remotely monitoring the consumer 200 can review thealert and confirm whether the active ingredient should be released intothe GI tract of the consumer 200. In this manner, the systemincorporating both the activation device 400 and the externalcommunication device 210 may be used to double check the measurementstaken by the activation device 400 and provide the consumer or remotemonitor (e.g., a doctor or health care professional) with theopportunity to confirm that the active ingredient should in fact bedispensed. This can reduce or eliminate erroneous distribution of activeingredient.

Once the health event measured by activation device 400 is confirmed,the consumer 200 or remote monitor can approve the dispensing of theactive ingredient through a user interface of the external communicationdevice 210, which in turn produces the signal 413 from the externalcommunication device 210 to the consumable capsule 220. The signal 413and communication between the external communication device 210 andconsumable capsule 200 can be similar or identical to the embodimentsdescribed above with respect to FIG. 2.

While not shown in FIG. 4B, the illustrated system can incorporate asecondary transceiver within the activation device 400 as described inreference to FIG. 3 so that the signal between the activation device 400and the external communication device 210 can be relayed over longerdistances than would be possible without the secondary transceiver. Thesecondary transceiver may be within a separate activation device fromthe activation device 400 and worn on a separate part of the body fromthe activation device 400, or the secondary transceiver may beincorporated into the activation device 400.

The activation device used in the embodiments described above isgenerally not limited and can be used to monitor one or more of anynumber of characteristics relating to a user's health. A wide variety ofactivation devices currently exist that are worn all over the human bodyto monitor any number of vital signs, health characteristics, and thelike. Examples include, but are not limited to, headsets that measurebrainwaves, glucose monitors, ECG monitors, pulse oximeters, bloodpressure monitors, temperature monitors, EKG monitors, EGG monitors, EMGmonitors, heart activity monitors, skin moisture monitors, breathingmonitors, swelling monitors, and cardiac monitors.

With reference to FIG. 5A, a diagrammatic representation of anembodiment of a system in which the consumer 200 wears activation device500 around the consumer's abdomen or chest is shown. In some examples,the activation device 500 may be incorporated into a belt, pants, orshirt that is worn around the consumer's abdomen. The activation device500 may include a coil of wire that generates an electromagnetic signal511 that provides power to the consumable capsule 220 and triggers therelease of the active ingredient into the consumer's GI tract. Byencircling the consumer's abdomen or chest, the electromagnetic signal511 generated by the activation device 500 may transfer power to theconsumable capsule 220 more efficiently. In addition, theelectromagnetic signal 511 may reach a larger area of the consumer's GItract. The activation device 500 may trigger the release of the activeingredient based on an input from the consumer 200, an input from ahealth provider, and/or based on one or more aspects of the consumer'shealth, as described in reference to FIGS. 1-4.

In some embodiments, the coil of wire included in the activation device500 may be litz wire. The litz wire may provide reduced impedance andallow the electromagnetic signal 511 to be generated more efficiently.The activation device 500 may also include a power source, such as abattery, and a secondary transceiver for communicating with otherdevices (such as an external communication device 210). In addition, theactivation device 500 may include geolocation technology (e.g., GPS)and/or health monitoring technology.

In some embodiments, the activation device 500 may provide telemetry asto the location of the consumable capsule 220 within the consumer's 200GI tract. For example, the consumable capsule 220 may cause interferenceto an electromagnetic field generated by the activation device 500. Theactivation device 500 may then estimate the location of the consumablecapsule 220 based at least in part on this interference. The release ofthe active ingredient may then be triggered by the activation device 500when the consumable capsule 220 is in a particular portion of the GItract.

In addition, the activation device 500 may detect that the activeingredient has been released by the consumable capsule 220 based on oneor more characteristics of the consumable capsule 220. For example, theconsumable capsule 220 may cause different amounts of interference to anelectromagnetic field generated by the activation device 500 before andafter the release of the active ingredient. Alternatively, theconsumable capsule 220 may provide a feedback signal to the activationdevice 500 when the active ingredient is released. In some embodiments,the consumable capsule 220 may release more than one active ingredient,and/or multiple doses of an active ingredient. Thus, the consumablecapsule 220 may cause different amounts of interference and/or differenttypes feedback based on type and/or amount of active ingredient that wasreleased.

In some embodiments, the activation device 500 may utilize one or twomagnetic coils for generating the electromagnetic signal 511. Two coilsmay be configured in a Helmholtz arrangement and may provide anapproximately uniform magnetic field between the two coils. However,this configuration may only be capable of producing a magnetic fieldalong a single axis, and may require the consumable capsule 220 toincorporate three orthogonal receiving coils. This configuration mayreduce the complexity of the activation device 500 at the expense ofincreasing the complexity of the consumable capsule 220.

Alternatively, a lower cost and lower complexity consumable capsule 220may be used with an activation device 500 that incorporates an array ofsmaller coils. Each of the smaller coils may be independently controlledto produce a magnetic field with an arbitrary orientation and gradient.This multi-coil architecture may allow the consumable capsule 220 torespond to electromagnetic signals 511 in a single axis because theactivation device 500 can continuously adjust its field generation tomatch the orientation of the consumable capsule 220.

A set of individual coils may be arranged in the activation device 500such that six or more coils can operate concurrently to behave as a setof Helmholtz coils, or to generate a gradient with orientation,magnitude, and RF emissions suitable for interacting with the consumablecapsule 220 in a variety of orientations. For example, one embodimentmay include 8 or 12 coils circumscribing the consumer's body in ahorizontal row. Three or four of these rows of coils may be stackedvertically along the body to cover a larger area of the consumer's GItract. The coils may be circular, square, hexagonal, or other suitableshapes. The coils may be made of copper, aluminum, or other suitableconductors, and may be flexible wires or rigid wires. Flexible printedcircuit board manufacturing techniques may be used to etch multiplecoils onto a single substrate that may also contain the control andpower electronics necessary to operate the activation device 500.

In order to effectively utilize the set of coils, the activation device500 may be capable of sensing the approximate location and orientationof the consumable capsule 220. This location sensing may be implementedby scanning for the consumable capsule 220 by adjusting the fieldorientation until the activation device 500 is coupled with theconsumable capsule 220. The location data that results from thisscanning process may be used to control the delivery of a particularactive agent or collection of a sample within the body, as needed byclinical applications. In some embodiments, the capsule localizationprocess may be implemented such that the activation device 500 detectsthe electrical power absorbed by the consumable capsule 220. Thistechnique may allow the activation device 500 to output a minimum amountof power necessary to satisfy the requirements of the consumable capsule220. The reduction of output power may improve battery life and reduceRF emissions of the activation device 500. Minimizing RF emissions maybe desirable for both reducing system heat and meeting US FCC andinternational regulations.

In some embodiments, the consumable capsule 220 may utilize one or morelight emitting diodes (LEDs) (such as shown in FIG. 6C). In theseembodiments, the detection of absorbed power may allow the activationdevice 500 to implement closed-loop control of the LED output.Implementing transmitter-side control of the capsule's light emissionsmay allow for precise activation of smart-polymer features such asvalves, as further described herein.

In addition, an activation device 500 utilizing a set of coils may becapable of powering, controlling, and communicating with multiplecapsules 220 within a consumer. For example, the activation device 500may be configured to create a complex magnetic field geometry thatsatisfies the requirements of multiple capsules 220 simultaneously.Increasing the number of independent coils in the activation device 500may improve the effectiveness of interacting with multiple capsules 220by allowing for increasingly complex field geometries.

In some embodiments, an activation device 500 utilizing a set of coilsmay be designed to react in real-time to environmental magneticdisturbances, such as nearby metallic objects, or large or moving bodytissues. If the activation device 500 is intended to be used innon-controlled environments such as an consumer's home, school, orworkplace, environmental, magnetic disturbances may pose a risk to theproper functionality of the system. Real-time control of the magneticfield orientation and gradient may allow the multi-coil activationdevice 500 to function in environments where a single coil activationdevice, or an activation device having single set of Helmholtz coilswould fail.

In some embodiments, an activation device 500 utilizing a set of coilsmay be used to control the movement of the consumable capsule 220. Forexample, the consumable capsule 220 may incorporate a permanent magnetor other means for locomotion driven by an external magnetic field.

With reference to FIG. 5B, a diagrammatic representation is shown of anembodiment of a system in which the consumer 200 again wears activationdevice 500. However, in the embodiment in FIG. 5B, a signal (or signals)513 is sent from an external communication device 210 to the activationdevice 500, which is then used to generate an electromagnetic signal511. In one embodiment, the electromagnetic signal 511 provides power tothe consumable capsule 220 and triggers the release of the activeingredient into the consumer's GI tract, as described in reference toFIG. 5A.

The activation device 500 may provide telemetry information to theexternal communication device 210 regarding the location of theconsumable capsule within the consumer's GI tract. For example, theconsumable capsule 220 may cause interference to an electromagneticfield generated by the activation device 500. The activation device 500may estimate the location of the consumable capsule 220 based at leastin part on this interference, and then report the estimated location tothe external communication device 210. The external communication device210 may then send the signal 511 to the activation device 500 based atleast in part on the telemetry information.

In addition, the activation device 500 may detect that the activeingredient has been released by the consumable capsule 220 based on oneor more characteristics of the consumable capsule 220. For example, theconsumable capsule 220 may cause different amounts of interference to anelectromagnetic field generated by the activation device 500 before andafter the release of the active ingredient. Alternatively, theconsumable capsule 220 may provide a feedback signal to the activationdevice 500 when the active ingredient is released. The activation device500 may then send a notification to the external communication device210 indicating that the active ingredient has been released. In someembodiments, the consumable capsule 220 may release more than one activeingredient, and/or multiple doses of an active ingredient. Thus, thenotification from the activation device 500 may also indicate the typeand amount of active ingredient that was released.

The activation device suitable for use in embodiments described hereincan also include camera-based eyewear technology, such as Google glassand the like. This camera-based eyewear technology may be used to, forexample, take pictures or video of a user's various body parts in orderto make diagnosis for conditions that manifest themselves externally ona user's body.

The activation device suitable for use in embodiments described hereinmay be freestanding (worn over or under clothes) or can be incorporatedinto clothes.

Activation device may also include devices/technology which areincorporated into/onto a mobile phone, tablet, PDA, or the like. Anyactivation device that is incorporated onto or into a mobile phone,tablet, etc., can be used. Examples of activation devices that areincorporated onto or into a mobile phone, tablet, etc. include, but arenot limited to, protective cases which can take the pulse of a user whenhis/her thumbs or fingers are placed on the protective case and softwarethat utilizes a mobile phone's camera to conduct eye exams or other eyerelated diagnostic tests.

In some embodiments, the activation device may also include implantabledevices in order to monitor vital signs and the like which cannotcurrently be monitored using external activation devices.

The consumable capsule further includes one or more active ingredients.Any active ingredient or combination of active ingredients can beincluded in the consumable capsule. In some embodiments, the activeingredients may include prescription pharmaceuticals, over-the-counterpharmaceuticals, veterinary pharmaceuticals, and/or other consumableproducts. Exemplary active ingredients include, but are not limited to,nutraceuticals, vitamins, supplements, minerals, enzymes, probiotics,bronchodilators, anabolic steroids, analeptics, analgesics, proteins,peptides, antibodies, vaccines, anesthetics, antacids, antihelmintics,anti-arrthymics, antibiotics, anticoagulants, anticolonergics,anticonvulsants, antidepressants, antidiabetics, antidiarrheals,anti-emetics, anti-epileptics, antihistamines, antihormones,antihypertensives, anti-inflammatories, antimuscarinics, antimycotics,antineoplastics, anti-obesity drugs, antiprotozoals, antipsychotics,antispasmotics, anti-thrombics, antithyroid drugs, antitussives,antivirals, anxiolytics, astringents, beta-adrenergic receptor blockingdrugs, bile acids, bronchospasmolytic drugs, calcium channel blockers,cardiac glycosides, contraceptives, corticosteriods, diagnostics,digestives, diuretics, dopaminergics, electrolytes, emetics, haemostaticdrugs, hormones, hormone replacement therapy drugs, hypnotics,hypoglycemic drugs, immunosuppressants, impotence drugs, laxatives,lipid regulators, muscle relaxants, pain relievers,parasympathicolytics, parasympathicomimetics, prostagladins,psychostimulants, sedatives, sex steroids, spasmolytics, sulfonamides,sympathicolytics, sympathicomimetics, sympathomimetics, thyreomimetics,thyreostatic drugs, vasodialators, and xanthines; drugs or medicaments,breath fresheners, vitamins and other dietary supplements, minerals,caffeine, nicotine, fruit juices, and the like, and mixtures thereof.Examples of useful drugs include ace-inhibitors, antianginal drugs,anti-arrhythmias, anti-asthmatics, anti-cholesterolemics, analgesics,anesthetics, anti-convulsants, anti-depressants, anti-diabetic agents,anti-diarrhea preparations, antidotes, anti-histamines,anti-hypertensive drugs, anti-inflammatory agents, anti-lipid agents,anti-manics, anti-nauseants, anti-stroke agents, anti-thyroidpreparations, anti-tumor drugs, anti-viral agents, acne drugs,alkaloids, amino acid preparations, anti-tussives, anti-uricemic drugs,anti-viral drugs, anabolic preparations, systemic and non-systemicanti-infective agents, anti-neoplastics, anti-parkinsonian agents,anti-rheumatic agents, appetite stimulants, biological responsemodifiers, blood modifiers, bone metabolism regulators, cardiovascularagents, central nervous system stimulates, cholinesterase inhibitors,contraceptives, decongestants, dietary supplements, dopamine receptoragonists, endometriosis management agents, enzymes, erectile dysfunctiontherapies such as sildenafil citrate, which is currently marketed asViagra®, fertility agents, gastrointestinal agents, homeopathicremedies, hormones, hypercalcemia and hypocalcemia management agents,immunomodulators, immunosuppressives, migraine preparations, motionsickness treatments, muscle relaxants, obesity management agents,osteoporosis preparations, oxytocics, parasympatholytics,parasympathomimetics, prostaglandins, psychotherapeutic agents,respiratory agents, sedatives, smoking cessation aids such asbromocryptine or nicotine, sympatholytics, tremor preparations, urinarytract agents, vasodilators, laxatives, antacids, ion exchange resins,anti-pyretics, appetite suppressants, expectorants, anti-anxiety agents,anti-ulcer agents, anti-inflammatory substances, coronary dilators,cerebral dilators, peripheral vasodilators, psycho-tropics, stimulants,anti-hypertensive drugs, vasoconstrictors, migraine treatments,antibiotics, tranquilizers, anti-psychotics, anti-tumor drugs,anti-coagulants, anti-thrombotic drugs, hypnotics, anti-emetics,anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- andhypo-glycemic agents, thyroid and anti-thyroid preparations, diuretics,anti-spasmodics, terine relaxants, anti-obesity drugs, erythropoieticdrugs, anti-asthmatics, cough suppressants, mucolytics, DNA and geneticmodifying drugs, and combinations thereof.

The consumable capsule may contain active ingredients having varioustypes of payload form, such as powder, liquid, oil, slurry, micro-beads,nano-beads, etc. The active ingredients can be included in theconsumable capsule in any desired quantity and in any desiredcombination. For example, the quantity of active ingredient contained ina consumable capsule may range from 0.1 mg to 500 g. However, thequantity may not be limited to these ranges.

In some embodiments, the consumable capsule may release more than oneactive ingredient, and/or multiple doses of an active ingredient.

The active ingredients selected for use in the consumable capsule can beused to address a variety of conditions. In some embodiments, the activeingredients are selected from those generally used to enhance physicalperformance, such as stimulants, electrolytes, vitamins, and minerals.In such embodiments, the consumable capsule matrix can be used todeliver any of the active ingredients on demand and in response to aspecific event in an athletic competition (e.g., an on demand release ofcaffeine at the beginning of a steep climb in a bicycle race). In someembodiments, the active ingredients can be medicine needed to treatand/or prevent a variety of conditions. In a specific example, theactive ingredients are selected to treat life threatening conditions,such as in a human having a high risk for heart attacks, in which casethe consumable capsule can provide nitroglycerin on demand (andpotentially by a remote user, such as a doctor, monitoring such apatient). In still another embodiment, the active ingredient can be anytype of appetite suppressant such that the consumable capsule can beused by individuals trying to lose weight. In such embodiments, theconsumable capsule can be used to deliver the appetite suppressant ondemand, such as when the user feels a food craving.

In some embodiments, a user can consume multiple consumable capsules,with each consumable capsule having different active ingredients orcombinations of active ingredients. Each consumable capsule can furtherinclude internal electronic components that transmit and/or receivespecific signals different from the signals used in the other consumablecapsule such that the active ingredients in each consumable capsule canbe released separately and independently from active ingredients in theother consumable capsule. The user interface of the externalcommunication device may be used to select which active ingredients torelease. In a specific example, a first consumable capsule includeselectrolytes and a second consumable capsule includes caffeine. In suchan embodiment, the user may use the external communication device torelease the caffeine when desired and the electrolytes when desired.

Other components that can be included in the consumable capsule includecomponents which help to establish the form and/or stability of theconsumable capsule, such as binding agents, coating materials, and shelllayers. Any suitable binding agents, coating materials, and/or shelllayers can be used to create a consumable capsule in which the internalelectronic components and the active ingredients are embedded. Theconsumable capsule may be created in a range of sizes capable of beingconsumed by a human or other animal. For example, the length of thecapsule may range from 1 mm to 10 cm, and the diameter may range from 1mm to 5 cm. However, the consumable capsule may not be limited to theseranges.

In some embodiments, the binding agents, coating materials, shelllayers, or the like are selected such that the internal electroniccomponents can carry out a release activity which causes the bindingagents, coating materials, shell layers, or the like to change in someway that allows the active ingredients to release into user. Anysuitable release activity that results in the active ingredients beingreleased from the consumable capsule into the consumer can be used toallow for the release of the active ingredients. In some embodiments,the release activity is a heating event which results in the bindingagents, coating materials, etc., disintegrating, melting, or altering insome way that allows the active ingredients to release out of theconsumable capsule. In other embodiments, the release activity is avibrating or sonicating event that similarly causes a physical orstructural break down in the consumable capsule to thereby release theactive ingredients. Depending on the event to be initiated/carried outby the internal electronic components, the consumable capsule caninclude additional components necessary for carrying out the specificevent (e.g., a heating element, a light generating element, or avibrating element turned on and off by the electronic components uponreceipt of a signal by the internal receiver).

With reference to FIG. 6A, an example of a consumable capsule 600 isshown, in accordance with various aspects of the present disclosure.

In some embodiments, the material used to create a consumable capsule inwhich the internal electronic components and active ingredients areenclosed is designed and/or selected such that the consumable capsuledoes not significantly break down upon exposure to the user's GI tract.In other words, the consumable capsule should not be permitted tosignificantly break down and release active ingredients into the userbased on the conditions of the user's GI tract alone. The consumablecapsule can therefore include coating layers and/or shells or the likewhich are not capable of breaking down when exposed to the environmentof the user's GI tract, but which do break down upon the occurrence ofthe release activity initiated by the internal electronic components.Examples of specific materials and components are further described inreference to FIGS. 7A-12C.

With reference now to FIG. 6A, a diagrammatic representation of anembodiment of a system for powering and triggering a consumable capsule220 is shown. The system includes an external communication device 210,activation device 500, and a consumable capsule 220.

The external communication device 210 may include a user interface 605.A consumer may input a command through the communication device userinterface 605 for the consumable capsule 220 to release an activeingredient. The communication device user interface 605 may also includea display or other indicator that informs the consumer of the status ofthe consumable capsule 220. For example the communication device userinterface 605 may provide an indicator when the active ingredient wassuccessfully released from the consumable capsule 220.

When the communication device user interface 605 receives a command forthe consumable capsule 220 to release an active ingredient, thecommunication device 210 may activate a communications module 610. Thetransceiver 610 transmits a signal (or signals) to the activation device500. The transmitted signal instructs the activation device 500 totrigger the consumable capsule 220 to release the active ingredient. Thesignal may be transmitted using a wireless communication protocol, suchas Bluetooth or Near Field Communication (NFC).

The activation device 500 includes a transceiver 615 for receiving thesignal (or signals) from the external communication device 210. Thereceived signal is passed to a controller module 620, which interpretsthe received signal and determines that an instruction to release theactive ingredient was sent by the external communication device 210. Insome embodiments, the activation device 500 may also include a userinterface 625. The user interface 625 may include a display orindicator. The user interface 625 may indicate that an instruction torelease the ingredient was successfully received. In some embodiments,the consumer inputs a command through the wearable user interface 625for the consumable capsule 220 to release the active ingredient, insteadof inputting the command through the external communication device 210.

The activation device 500 also includes a power source 630. The powersource 630 may be a battery or other portable power source. The powersource 630 provides power to the components of the activation device. Insome embodiments, the power source 630 is also the source of power forthe consumable capsule 220, as further described herein. A powermanagement module 635 receives power from the power source anddistributes the power to the components of the activation device 500.

When an instruction to release the active ingredient is received by theactivation device 500, the controller module 620 configures the powermanagement module 635 to supply power to drive electronics 640. Thedrive electronics 640 include electronic components (such as amplifiersand filters) that condition the power from the power management module635. The conditioned power is then used to drive a transmitting element,such as primary coil 645. The primary coil 645 functions as an antennato emit an electromagnetic signal at a frequency and amplitude capableof inductively coupling with orthogonal secondary coils 650 within theconsumable capsule 220.

The orthogonal secondary coils 650 within the consumable capsule 220include three coils 652, 654, 656 arranged at right angles to oneanother. Each of the antenna coils 652, 654, 656 is configured toreceive electromagnetic energy from the electromagnetic signal emittedby the activation device 500. The respective amount of electromagneticenergy received by each of the coils 652, 654, 656 depends on theorientation of the consumable capsule 220 and distance from the primarycoil 645. The orthogonal secondary coils 650 allow the consumablecapsule 220 to efficiently receive the energy from the electromagneticsignal while the consumable capsule 220 is in a variety of orientationswithin a consumer's GI tract. For example, the coil 652, 654, or 656having an orientation closest to the orientation of the primary coil 645of the activation device 500 may receive a larger amount ofelectromagnetic energy than the other coils. Thus, the orthogonalsecondary coils 650 allow the total amount of electromagnetic energyreceived by the consumable capsule 220 to be substantially independentof the orientation of the consumable capsule 220.

The electromagnetic energy received by each of the coils 652, 654, 656may be used to provide power to the consumable capsule 220. For example,one or more of the coils 652, 654, 656 may generate low-level AC signalsfrom the electromagnetic energy emitted by the primary coil 645 byinductively coupling with the primary coil 645. The size of the ACsignals generated by each of the coils 652, 654, 656 may depend on theorientation of the consumable capsule 220 relative to the primary coil645. Each of the AC signals generated by the coils 652, 654, 656 aretransmitted to the consumable capsule's control electronics 660. Thecontrol electronics 660 include power management circuitry 662 whichconverts the AC signals from the coils 652, 654, 656 into a power sourcefor the consumable capsule 220. For example, the power managementcircuitry 662 rectify, filter, and combine the low-level AC signals toproduce a DC power source capable of powering the various functions ofthe consumable capsule 220 (as shown in FIG. 6B). Alternatively, thepower management circuitry 662 may filter and combine the low-level ACsignals to produce an AC power source. In this way, the orthogonalsecondary coils 650 and power management circuitry 662 allow theconsumable capsule 220 to be powered without the use of a potentiallyharmful chemical battery.

The consumable capsule's power management circuitry 662 provides powerto a controller module 664. The controller module 664 may then triggerthe release of an active ingredient by activating a first compartmentactuator 670 and/or a second compartment actuator 675. When acompartment actuator is activated, an opening is created in theconsumable capsule 220 which allows the active ingredient within arespective compartment to be released into a consumer's GI tract. Thecontroller module 664 may be configured to activate the first and secondcompartment actuators 670, 675 sequentially or simultaneously. Whenactivated sequentially, the controller module 664 may activate thesecond compartment actuator 675 automatically at a predetermined timeafter receiving the electromagnetic signal from the activation device'sprimary coil 645. Alternatively, the controller module 664 may activatethe second compartment actuator 675 after receiving a secondaryelectromagnetic signal from the activation device's primary coil 645.

In some embodiments, the predetermined time for activating the secondcompartment actuator 675 may be configured by the consumer. For example,the consumable capsule 220 may include a communications module 666 whichreceives commands from the activation device transceiver 615 and/or fromthe communication device transceiver 610. Based on the received command,the controller module 664 may configure the predetermined time foractivating the second compartment actuator 675. The communicationsmodule 666 may also be used for reporting the status of the consumablecapsule 220 to the activation device 500 and/or the externalcommunication device 210. For example, the controller module 664 mayinstruct the communications module 666 to transmit a feedback signalindicating each time a compartment actuator is successfully activated.The wearable transceiver 645 and/or communication device transceiver mayreceive the indicator, and then notify the consumer through thecommunication device user interface 605 and/or the wearable userinterface 625.

Alternatively, in some embodiments, the activation device 500 may detecta compartment actuator was successfully activated through othercharacteristics of the consumable capsule 220. For example, when acompartment actuator is activated, the amount of interference theconsumable capsule 220 causes to the electromagnetic field generated bythe primary coil 645 may change. The drive electronics 640 may includecircuitry for detecting this change in interference, which may then bereported to the wearable controller module 620. The wearable controllermodule 620 may then use the wearable user interface 625 to notify theuser that the active ingredient was successfully released, or thewearable controller module 620 may send a notification signal to theexternal communication device 210.

With reference now to FIG. 6B, a diagrammatic representation of anembodiment of the consumable capsule power management circuitry 662 isshown. As described in reference to FIG. 6A, drive electronics 640within the activation device provides power to the primary coil 645,which emits an electromagnetic signal. The primary coil 645 mayinductively couple with one or more coils 652, 654, 656 based on therelative orientation of each coil and their distance from the primarycoil 645. When the coils 652, 654, 656 inductively couple with theprimary coil 645, the electromagnetic energy emitted by the primary coil645 is converted into low-level AC signals by each of the coils 652,654, 656. The low-level AC signal generated by the coil 652 is filteredand rectified by capacitor 672 and diodes 682A and 682B. The low-levelAC signal generated by the coil 654 is filtered and rectified bycapacitor 674 and diodes 684A and 684B, and the low-level AC signalgenerated by the coil 656 is filtered and rectified by capacitor 676 anddiodes 686A and 686B. The filtered and rectified signals chargecapacitor 692, which supplies a substantially DC signal to a powerregulation circuit 690. The power regulation circuit 690 further smoothsthe DC signal and acts as a buffer between the power managementcircuitry 662 and the consumable capsule controller module 664. The DCsignal from the power regulation circuit 690 is used by the controllermodule 664 to activate one or more compartment actuators within theconsumable capsule. Alternatively, in some embodiments, the DC signalfrom the power regulation circuit may supplied directly to one or morecompartment actuators or light emitting diodes (LEDs).

With reference now to FIG. 6C, a diagrammatic representation of analternative embodiment of the electronics within the consumable capsuleis shown. The components shown in FIG. 6C may be an example of theconsumable capsule power management circuitry 662 described in referenceto FIGS. 6A and 6B. As described in reference to FIGS. 6A and 6B, thedrive electronics 640 of an activation device provide power to a primarycoil 645, which emits an electromagnetic signal. The primary coil 645may inductively couple with one or more of the coils 652, 654, 656within the consumable capsule. When the coils 652, 654, 656 inductivelycouple with the primary coil 645, the electromagnetic energy emitted bythe primary coil 645 is converted into low-level AC signals by each ofthe coils 652, 654, 656. The low-level AC signals generated by the coil652 are filtered and rectified by capacitors 672, 674, 676 and diodes682C, 682D, 684C, 684D, 686C, 686D. The rectified signal may thenprovide power to a light emitting diode (LED) 694 and/or other load 696within the consumable capsule.

In some embodiments, the capacitors 672, 674, 676 may be in series withone or more inductors (not shown). Alternatively, in some embodiments,the capacitors 672, 674, 676 may be in parallel with one or moreresistors or inductors (not shown). The combination of capacitors 672,674, 676 with inductors may allow the consumable capsule to efficientlycouple with the activation device when the activation device emits asignal within certain frequency bands. For example, the activationdevice may emit signals in the 125 Khz band and the 13.54 Mhz band (eachbeing available for unlicensed medical operation by the FCC). Eachfrequency band may be associated with a different behavior of theconsumable capsule. For example, a simple two-channel system might beimplemented to open and close an actuator of the consumable capsule. Theactivation device may emit at a frequency band associated with openingthe actuator, and emit at another frequency band associated with closingthe actuator. The activation device may be designed such that theprimary coil 645 is capable of emitting a signal at each frequency band,or the activation device may include multiple coils, each correspondingto a specific frequency band.

In addition to the LED 694, one or more of the diodes 682C, 682D, 684C,684D, 686C, 686D shown in FIG. 6C may optionally also be LEDs. TheseLEDs may be selected to emit light at different wavelengths, and may beused to activate one or more compartment actuators of the consumablecapsule. For example, different wavelengths may be associated withdifferent compartments of the consumable capsule. Alternatively or inaddition, certain wavelengths may be associated with opening acompartment actuator, while other certain wavelengths may be associatedwith closing a compartment actuator. Specific LEDs 682C, 682D, 684C,684D, 686C, 686D may be activated based on the frequency of theelectromagnetic signal emitted by the activation device, as describedabove. For example, LEDs 682C and 682D may be activated when theactivation device emits a signal that couples with coil 652.

Inductive power coupling typically requires rectification circuitrywhich converts the AC power waveform from the resonant LC receivercircuit to DC power that can be used by the load. For example, FIG. 6Buses (non-LED) diodes to provide this rectification, but these diodesmay add complexity to the system and may reduce power deliveryefficiency due to energy lost as heat. The circuitry shown in FIG. 6Creplaces the conventional diodes with LEDs 682C, 682D, 684C, 684D, 686C,686D, and then uses the light emitted by the LEDs in the process ofopening compartments of the consumable capsule. This approach allowssome of the power that would have been wasted on the rectification stageto now perform useful work as emitted light. The total number ofdiscrete components in the system may be thereby reduced.

With reference now to FIG. 7A, a partial cross-sectional viewillustrating an example of an embodiment of a consumable capsule 700 isshown, in accordance with various aspects of the present disclosure.FIGS. 7B and 7C further illustrate sectional views of the consumablecapsule 700.

The consumable capsule 700 includes orthogonal secondary coils 705 andcontrol electronics 710. The orthogonal secondary coils 705 and controlelectronics 710 are enclosed within an electronics section 715. Theconsumable capsule 700 also includes a compartment section 740 having afirst delivery compartment 720 and a second delivery compartment 725.The first delivery compartment is formed by a first wall 782 and asecond wall 784 of the compartment section 740. The first wall 782 andthe second wall 784 are connected by a first primary support column 775(shown in FIGS. 7B and 7C) and a second primary support column 780. Thefirst delivery compartment 720 is sealed by a first linear actuator 730.Secondary support columns 765 embedded within the first linear actuator730 provide further support between the first wall 782 and the secondwall 784 of the compartment section 740.

The second delivery compartment 725 is formed by the second wall 784 anda third wall 786 of the compartment section 740. The first supportcolumn 775 (shown in FIGS. 7B and 7C) and the second support column 780further connect the second wall 784 and the third wall 786. The seconddelivery compartment 725 is sealed by a second linear actuator 735.Secondary support columns 770 embedded within the second linear actuator735 provide further support between the second wall 784 and the thirdwall 786 of the compartment section 740.

In some embodiments, the electronics section 715 and the compartmentsection 740 may be manufactured independently. The electronics section715 may then be bonded to the first wall 782 of the compartment section740 through various bonding techniques, such as sonic welding or with anadhesive. The electronics section 715 and the compartment section 740may be made from the same or different materials. For example, theelectronics section 715 may be made from an inert material that is notdigestible (e.g., polyethylene), while the compartment section 740 maybe made from a digestible material (e.g., polylactic-co-glycolic acid(PLGA)).

In other embodiments, the electronics section 715 and the compartmentsection 740 may be manufactured as a single structure from the samematerial, either inert or digestible.

Each delivery compartment 720 and 725 may include an active ingredient.While shown with two delivery compartments, one of ordinary skill wouldunderstand the consumable capsule 700 may be configured with a singledelivery compartment, or three or more delivery compartments.

The orthogonal secondary coils 705 include three coils arrangedorthogonally to one another. Each of the coils are configured to receiveelectromagnetic energy from a triggering device, such as the activationdevice described above. The respective amount of electromagnetic energyreceived by each of the coils depends on the orientation of theconsumable capsule 700. The orthogonal secondary coils 705 allows theconsumable capsule to efficiently receive signals (such as anelectromagnetic signal 511 from activation device 500, shown in FIGS. 5Aand 5B) while the consumable capsule 700 is in a variety of orientationswithin a consumer's GI tract. For example, the activation device 500 maygenerate an electromagnetic signal 511 using a primary coil of wire. Thecoil of the orthogonal secondary coils 705 having an orientation closestto the orientation of the coil of the activation device may receive alarger amount of electromagnetic energy than the other coils. Thus, byincluding the three orthogonal coils in the orthogonal secondary coils705, the total amount of electromagnetic energy received by theconsumable capsule 700 may be substantially independent of theorientation of the consumable capsule 700.

The energy received by each of the coils of the orthogonal secondarycoils 705 may be used to provide power to the consumable capsule 700.Control electronics 710 may combine the energy received by each of thecoils and convert the total received energy into a power source, asdescribed in reference to FIGS. 6A-6C. In this way, the orthogonalsecondary coils 705 and control electronics 710 allow the consumablecapsule 700 to generate power without the use of a potentially harmfulchemical battery.

The control electronics 710 trigger the release of the active ingredientin the first delivery compartment 720 by applying an electric field tothe first linear actuator 730. The control electronics 710 apply theelectric field by transmitting an electric current over a first positivepower line 745 and a first negative power line 750 (shown in FIG. 7B) tothe first linear actuator 730. The first linear actuator 730 may includea stimuli responsive material such that when the electric field isapplied to the first linear actuator 730, the actuator changes shape.When the first linear actuator 730 changes shape, an opening is createdfor the active ingredient within the first delivery compartment 720 tobe released. The control electronics 710 trigger the release of theactive ingredient in the second delivery compartment 730 in a similarway. The second linear actuator 735 may also include a stimuliresponsive material and the control electronics 710 may apply anelectric field to the second linear actuator 735 by transmitting anelectric current over a second positive power line 755 and a secondnegative power line 760. The control electronics 710 may be configuredto trigger the first and second delivery compartments sequentially orsimultaneously, as described above.

The linear actuators 730 and 735 may be made partially or entirely fromstimuli responsive materials, such as electro-active polymers (EAPs). Inone embodiment, the EAPs include Inherently Conjugated Polymers (ICPs),such as Polypyrrole, Polyaniline, or Polythiopene. When a voltagepotential is applied to an ICP, electrons begin moving between theelectrodes in the polymer. The speed of this is driven by thesurrounding electrolyte ionic conductivity. The movement of charge thenattracts ions in the polymer to the electrodes, creating a redoxreaction. Ions from the electrolyte diffuse into the polymer to balancethe charge in the system, the speed of which is driven by the size ofthe ions and the structure of the polymer. In some examples, thedigestive fluids within the GI tract may function as the electrolyte.The addition of these ions then generates a volume change in the polymerdependent on the modulus of the polymer. The volume change creates ageometric change which is dependent on the shape of the actuator and/orthe materials to which the actuator is attached.

The components of the consumable capsule 700 may include bio-compatiblecomponents. For example, the components within the orthogonal secondarycoils 705 and control electronics 710 may include conductors,semi-conductors, dielectric materials, and substrate materials.Bio-compatible conductors may be made from Magnesium or Magnesium alloymaterials. Bio-compatible semi-conductors may be made from Indigoids,Magnesium Oxide, or doped Magnesium materials. Bio-compatibledielectrics may be made from nucleotides or DNA. Bio-compatiblesubstrates may be made from Silk, PLGA, or Shellac. In addition to beingbio-compatible, some of the components (such as those made from PLGA,Indigoids, and nucleotides) may be bio-resorbable.

With reference now to FIG. 7D, a partial cross-sectional viewillustrating an example of an alternative embodiment of the consumablecapsule 700 is shown, in accordance with various aspects of the presentdisclosure. FIGS. 7E and 7F further illustrate sectional views of thealternative embodiment of the consumable capsule 700.

In this embodiment, the actuators 730 and 735 are partially or entirelymade from a stimuli responsive material that utilizes photo-responsivesmart shape-changing polymers or liquid crystalline elastomers (LCE), asfurther described herein. The photo-responsive smart shape-changingpolymers use photons or light as an energy input. The photons or lightare generated by LEDs 792 and 794. The LEDs 792 and 794 may be one ormore of the rectification diodes 682C, 682D, 684C, 684D, 686C, 686D, orthe LED 694, described in reference to FIG. 6C. In some embodiments,each of the LEDs 792 and 794 may include multiple LEDs capable ofemitting light at different wavelengths. The control electronics 710provide power to LED(s) 792 over the first positive power line 745 andthe first negative power line 750 (shown in FIG. 7E). When the LED(s)792 emits light, the photo-responsive actuator 730 changes shape and anopening is created for the active ingredient within the first deliverycompartment 720 to be released. In a similar way, the controlelectronics 710 provide power to LED(s) 794 over the second positivepower line 755 and the second negative power line 760, which causes thephoto-responsive actuator 735 to change shape.

These types of photo-responsive actuators 730 and 735 have a number offeatures such as ability to be remotely controlled with high speed andspatial precision, have large strain actuation, require low voltage,work at room temperature or body temperature, can operate in liquidelectrolytes or body fluids, and can be microfabricated. Photon energymay be converted to mechanical work in the photo-responsive actuators730 and 735 using two major mechanisms: reversible structural changeupon photo irradiation such as photo-isomerization, charge generation,or initiation of reversible photochemical reaction within the polymer;or local temperature increase upon absorption of photons by the materialthat leads to actuation in thermal responsive polymer actuators.

In one embodiment, reversible photo-isomerization polymer actuators 730and 735 may be used. Reversible photo-isomerization polymer actuators730 and 735 can store external tensile or compression force input as apotential energy and return to their original form upon removal offorces by converting the potential energy to mechanical work.Alternatively, reversible photo-isomerization polymer actuators 730 and735 may return to their original form by using a different wavelength oflight and/or using heat (such as body temperature). Light orphoto-irradiation from the LEDs 792 and 794 may be used to convertenergy into motion quickly by using photo-responsive macromolecules inthe actuators 730 and 735 that are light-energy transducers.Photochemical molecules such as spyropyranes, stilbenes, fulgides, andazobenzenes can change their structure when irradiated with light at acertain wavelength. This structural change results in a local volumechange that can be amplified if it is incorporated into the polymerchain; and therefore, exhibit actuation. Azobenzene may be preferred dueto its thermal stability and rapid reaction at certain absorbance withreversible property. The azobenzene isomers can be isomerized from transto cis upon UV light irradiation at 343 nm and from cis to trans uponvisible light irradiation at 440 nm. The LEDs 792 and 794 may be capableof emitting light at approximately each of these wavelengths. This maybe achieved using one or more LEDs. It is noted that the cis isomer isless stable than the trans isomer due to the steric hindrance;therefore, the cis isomer can also relax back to trans isomerisothermally which is thermodynamically more stable. Overall, themolecules of the actuators 730 and 735 transform from a straightconfiguration (trans) to a bent configuration (cis), which isresponsible for the shape change of the actuators, as shown in FIGS.8D-8F.

Photo-irradiation of azobenzene (azo) incorporated in liquid-crystallineelastomer (LCE) may induce a reversible 20% shape contraction. It isnoted that LCEs are class of stimuli-sensitive materials includingliquid-crystal molecules with exceptional actuation properties that canhave both elastic properties and anisotropy due to the presence ofliquid-crystalline order. One of the unique properties of azobenzene isthe reversible transition from trans to cis under UV light and by usinga longer wavelength of 440 nm to return the polymer rapidly to itsoriginal state. Upon UV light irradiation, an azobenzene actuator maytransform rapidly (0.5 second) to a bent or twisted shape.

The actuators 730 and 735 may include azo-LCE material that bends afterexposure to 366 nm light and reverts completely to its initial state byirradiating with natural light or exposure to heat (such as body heat).The ability to control bending reversibly using light exposure may allowfor faster response and less energy or power requirement. The azo-LCEmay be created using azobenzene mesogenic monomer capable ofphoto-actuation.

The azo-LCE actuators 730 and 735 may be bent after exposure to 366 nmlight with the intensity of 2.0 mW/cm-2 for 10 to 35 seconds. The bentazo-LCE actuators 730 and 735 may be completely recovered to theirinitial flat state after natural light irradiation. A bending maximumcan be reached after exposure of the azo-LCE actuators 730 and 735 to UVlight for about 35 to 50 seconds.

It is important to optimize the performance of the azo-LCE actuators 730and 735 by varying the amount of azobenzene, crosslinking density,actuator thickness or dimensions, or the power intensity of the LEDs 792and 794. The bending moment and actuation speed may be varied byaltering the chemistry and alignment of azo-LCE, varying the powerintensity of irradiated light, and/or changing the polarization angle ofthe irradiated light. The crosslink density can influence theactuation-generated force and speed by changing the anisotropy andrigidity of the network of each actuator 730 and 735. The lightintensity and exposure time may also influence actuation time and force.

FIG. 8A illustrates a partial cross-sectional view of an example of anembodiment of a consumable capsule 800, in accordance with variousaspects of the present disclosure. The consumable capsule 800 is anexample of the consumable capsule 700 shown in FIGS. 7A-7C after thedelivery compartments are opened. FIGS. 8B and 8C further illustratesectional views of the consumable capsule 800.

As described with reference to FIG. 7A, the first linear actuator 730changes shape when an electric field is applied. For example, the firstlinear actuator 730 may compress longitudinally and expandcircumferentially, as shown in FIG. 8A. Alternatively, the first linearactuator 730 may change shape in other ways, as further describedherein. The resulting shape of the first linear actuator 730 creates anopening which allows the active ingredient within the first deliverycompartment 720 to be released into the consumer's GI tract. The secondlinear actuator 735 changes shape to release an active ingredient in asimilar way. While shown with two delivery compartments, one of ordinaryskill would understand the consumable capsule 800 may be configured witha single delivery compartment, or three or more delivery compartments.

With reference now to FIG. 8D, a partial cross-sectional viewillustrating an example of an alternative embodiment of the consumablecapsule 800 is shown, in accordance with various aspects of the presentdisclosure. The consumable capsule 800 is an example of the consumablecapsule 700 shown in FIGS. 7D-7F after the delivery compartments areopened. FIGS. 8E and 8F further illustrate sectional views of thealternative embodiment of the consumable capsule 800.

As described with reference to FIG. 7D, the photo-responsive actuators730 and 735 change shape when light of certain wavelengths are emittedby the LEDs 792 and 794. For example, the photo-responsive actuators 730may compress longitudinally and expand circumferentially, as shown inFIG. 8D. Alternatively, the actuators 730 and 735 may change shape inother ways, as further described herein. The resulting shape of theactuators 730 and 735 create openings which allows the active ingredientwithin the delivery compartments 720 and 725 to be released into theconsumer's GI tract. In some embodiments, the photo-responsive actuators730 and 735 may return to the original shape (as shown in FIGS. 7D-7F)by emitting another wavelength of light with the LEDs 792 and 794. Eachof the LEDs 792 and 794 may include multiple LEDs capable of emittinglight at different wavelengths. While shown with two deliverycompartments, one of ordinary skill would understand the consumablecapsule 800 may be configured with a single delivery compartment, orthree or more delivery compartments.

With reference now to FIG. 9A, a partial cross-sectional viewillustrating an example of an embodiment of a consumable capsule 900 isshown, in accordance with various aspects of the present disclosure.FIGS. 9B and 9C further illustrate sectional views of the consumablecapsule 900.

The consumable capsule 900 includes orthogonal secondary coils 905 andcontrol electronics 910. The orthogonal secondary coils 905 and controlelectronics 910 are enclosed within an electronics section 915. Theconsumable capsule 900 also includes a compartment section 940 having afirst delivery compartment 920 and a second delivery compartment 925.The first delivery compartment is formed by a first wall 982 and asecond wall 984 of the compartment section 940. The first wall 982 andthe second wall 984 are connected by a first primary support column 975(shown in FIGS. 9B and 9C) and a second primary support column 980. Thefirst delivery compartment 920 is sealed by a first bending actuator 930and a first bending substrate 965.

The second delivery compartment 925 is formed by the second wall 984 anda third wall 986 of the compartment section 940. The first supportcolumn 975 (shown in FIGS. 9B and 9C) and the second support column 980further connect the second wall 984 and the third wall 986. The seconddelivery compartment 925 is sealed by a second bending actuator 935 andsecond bending substrate 970. The bending actuators 930 and 935 may bemade partially or entirely from stimuli responsive materials. Thebending substrates 965 and 970 may made from a bio-compatible metal orother bio-compatible, semi-rigid materials.

In some embodiments, the electronics section 915 and the compartmentsection 940 may be manufactured independently. The electronics section915 may then be bonded to the first wall 982 of the compartment section940 through various bonding techniques, such as sonic welding or with anadhesive. The electronics section 915 and the compartment section 940may be made from the same or different materials. For example, theelectronics section 915 may be made from an inert material that is notdigestible (e.g., polyethylene), while the compartment section 940 maybe made from a digestible material (e.g., polylactic-co-glycolic acid(PLGA)).

In other embodiments, the electronics section 915 and the compartmentsection 940 may be manufactured as a single structure from the samematerial, either inert or digestible.

Each delivery compartment may include an active ingredient. Thecomponents of the consumable capsule 900 may further includebio-compatible components, as described in reference to FIGS. 7A-7C.While shown with two delivery compartments, one of ordinary skill wouldunderstand the consumable capsule 900 may be configured with a singledelivery compartment, or three or more delivery compartments.

The orthogonal secondary coils 905 include three coils arrangedorthogonally to one another, as described in reference to FIGS. 7A-7C.The energy received by each of the coils of the orthogonal secondarycoils 905 may be used to provide power to the consumable capsule 900.Control electronics 910 may combine the energy received by each of thecoils and convert the total received energy into a power source, asdescribed in reference to FIGS. 6A-6C.

The control electronics 910 trigger the release of the active ingredientin the first delivery compartment 920 by applying an electric field tothe first bending actuator 930. The control electronics 910 apply theelectric field by transmitting an electric current over electrodes, suchas first positive power line 945 and first negative power line 950(shown in FIG. 9B) to the first bending actuator 930. When the electricfield is applied to the first bending actuator 930, the actuator changesshape. When the first bending actuator 930 changes shape, an opening iscreated for the active ingredient within the first delivery compartment920 to be released. The control electronics 910 trigger the release ofthe active ingredient in the second delivery compartment 930 in asimilar way. The control electronics 910 apply an electric field to thesecond bending actuator 935 by transmitting an electric current over asecond positive power line 955 and a second negative power line 960. Thecontrol electronics 910 may be configured to trigger the first andsecond delivery compartments sequentially or simultaneously, asdescribed above.

The bending actuators 930 and 935 may be made from electro-activepolymers (EAPs). The EAPs may include Inherently Conjugated Polymers(ICPs), such as Polypyrrole, Polyaniline, or Polythiopene. When avoltage potential is applied to an ICP, electrons begin moving betweenthe electrodes in the polymer. The speed of this is driven by thesurrounding electrolyte ionic conductivity. The movement of charge thenattracts ions in the polymer to the electrodes, creating a redoxreaction. Ions from the electrolyte diffuse into the polymer to balancethe charge in the system, the speed of which is driven by the size ofthe ions and the structure of the polymer. In some examples, thedigestive fluids within the GI tract may function as the electrolyte.The addition of these ions then generates a volume change in the polymerdependent on the modulus of the polymer. The volume change creates ageometric change which is dependent on the shape of the actuator, whatit is attached to, etc. For example, the polymer may shrink in volume.When the polymer is attached to a surface of another material that doesnot shrink (such as the bending substrates 965 and 970), the polymer maycause itself and the other material to curl or bend.

With reference now to FIG. 9D, a partial cross-sectional viewillustrating an example of an alternative embodiment of the consumablecapsule 900 is shown, in accordance with various aspects of the presentdisclosure. FIGS. 9E and 9F further illustrate sectional views of thealternative embodiment of the consumable capsule 900.

In this embodiment, the actuators 930 and 935 are partially or entirelymade from a stimuli responsive material that utilizes photo-responsivesmart shape-changing polymers, as described in reference to FIGS. 7D-7F.The photo-responsive smart shape-changing polymers use photons or lightas an energy input. The photons or light are generated by LEDs 992 and994. The LEDs 992 and 994 may be one or more of the rectification diodes682C, 682D, 684C, 684D, 686C, 686D, or the LED 694, described inreference to FIG. 6C. In some embodiments, each of the LEDs 992 and 994may include multiple LEDs capable of emitting light at differentwavelengths. The control electronics 910 provide power to LED(s) 992over the first positive power line 945 and the first negative power line950 (shown in FIG. 9E). When the LED(s) 992 emits light, thephoto-responsive actuator 930 changes shape and an opening is createdfor the active ingredient within the first delivery compartment 920 tobe released. In a similar way, the control electronics 910 provide powerto LED(s) 994 over the second positive power line 955 and the secondnegative power line 960, which causes the photo-responsive actuator 935to change shape.

The photo-responsive actuators 930 and 935 operate in a similar manneras described in reference to FIGS. 7D-7F. Overall, the molecules of thephoto-responsive actuators 930 and 935 transform from a straightconfiguration (trans) to a bent configuration (cis) in response to lightemitted by the LEDs 992 and 994, which is responsible for the shapechange of the actuators, as shown in FIGS. 10D-10F. The actuators 930and 935 may include azo-LCE material that bends after exposure to 366 nmlight and reverts completely to its initial state after irradiating withnatural light or exposure to heat (such as body heat). The azo-LCEactuators 930 and 935 may be bent after exposure to 366 nm light withthe intensity of 2.0 mW/cm-2 for 10 to 35 seconds, as further describedin reference to FIGS. 7D-7F.

FIG. 10A illustrates a partial cross-sectional view of an example of anembodiment of a consumable capsule 1000, in accordance with variousaspects of the present disclosure. The consumable capsule 1000 is anexample of the consumable capsule 900 shown in FIGS. 9A-9C after thedelivery compartments are opened. FIGS. 10B and 10C further illustratesectional views of the consumable capsule 1000.

As described with reference to FIG. 9A, the first bending actuator 930changes shape when an electric field is applied. As shown in FIG. 10A,the first bending actuator 930 may bend outward from the consumablecapsule. The bending is produced by the first bending actuator 930 beingattached to the first bending substrate 965. As the volume of the firstbending actuator 930 decreases due to the electric field applied by theelectronics section 910, the portion of the first bending actuator 930attached to the first bending substrate 965 is prevented from decreasingin volume by the same amount. This causes the first bending actuator 930to curl outward from the consumable capsule 1000. The resulting shape ofthe first bending actuator 930 creates an opening which allows theactive ingredient within the first delivery compartment 920 to bereleased into the consumer's GI tract. The second bending actuator 935changes shape to release an active ingredient in a similar way. Whileshown with two delivery compartments, one of ordinary skill wouldunderstand the consumable capsule 1000 may be configured with a singledelivery compartment, or three or more delivery compartments.

With reference now to FIG. 10D, a partial cross-sectional viewillustrating an example of an alternative embodiment of the consumablecapsule 1000 is shown, in accordance with various aspects of the presentdisclosure. The consumable capsule 1000 is an example of the consumablecapsule 900 shown in FIGS. 9D-9F after the delivery compartments areopened. FIGS. 10E and 10F further illustrate sectional views of thealternative embodiment of the consumable capsule 1000.

As described with reference to FIG. 9D, the photo-responsive actuators930 and 935 change shape when light of certain wavelengths are emittedby the LEDs 992 and 994. For example, the photo-responsive actuators 930may bend outward from the capsule, as shown in FIG. 8D. Alternatively,the actuators 930 and 935 may change shape in other ways, as furtherdescribed herein. The resulting shape of the actuators 930 and 935create openings which allows the active ingredient within the deliverycompartments 920 and 925 to be released into the consumer's GI tract. Insome embodiments, the photo-responsive actuators 930 and 935 may returnto the original shape (as shown in FIGS. 9D-9F) by emitting anotherwavelength of light with the LEDs 992 and 994. Each of the LEDs 992 and994 may include multiple LEDs capable of emitting light at the desiredwavelengths. While shown with two delivery compartments, one of ordinaryskill would understand the consumable capsule 1000 may be configuredwith a single delivery compartment, or three or more deliverycompartments.

In some embodiments, the actuators described in reference to FIGS.7A-10F may utilize other types of shape-changing materials or “smart”polymers, such as shape memory polymers and liquid-crystallineelastomers. Shape memory polymers (SMP) and Liquid-crystallineelastomers (LCE) exhibit similar behaviors to electro-active polymers(EAP) and shape memory alloys, however the mechanism of actuation isdifferent. The SMP or LCE material is initially formed in a particularshape (shape A), which is then mechanically deformed and fixed in adifferent shape (Shape B). For example, Shape B may correspond to theclosed shape of the actuators shown in FIGS. 7A-7C and 9A-9C, whileShape A may correspond to the open shape of the actuators shown in FIGS.8A-8C and 10A-10C. Upon the application of a stimulus, for example heator light, the crosslinking formed by the mechanical deformation intoShape B is released, either by thermal or photo-reactive cleaving of thecross-linked bonds, causing the SMP or LCE material to return to ShapeA. For example, light may be applied to a closed SMP or LCE actuator byusing an LED included in the consumable capsule, as described above. Thelight from the LED then causes the SMP or LCE actuator to change into anopen shape. This process may be repeatable in some cases, for instance,by applying different wavelengths of light which cause repeatingre-organization of the molecules in the material.

LCE materials differ from traditional polymers in that crystallineelements form part of the cross-linked structure. This gives severalpronounced differences in behavior for these materials versus polymers.Firstly, the physical response is more anisotropic, depending on thecrystalline structure of the material, which make them suitable for theactuators in the present systems, which move along a preferentialdirection or axis. They also can actuate with lower energy inputs, asthe disturbance of part of the crystalline structure causes the entirestructure to re-order in some cases.

Other advantages may appear with the use of SMP or LCE materials. Forexample, the shape memory behavior is based on the molecular structure,not the chemical composition of the polymer. This allows for a muchbroader range of tailored mechanical and chemical properties to beachieved with similar shape memory behavior. Also, SMP and LCE materialsdemonstrate response times that can be as short as pico-seconds, whichmay be advantageous for limiting the amount of electromagnetic energyinput to the human body to power the consumable capsule. The SMPmaterials may be bio-compatible/bio-resorbable and may include PLGA andother bio-compatible/bio-resorbable materials. The LCE materials may bedoped with Thio-indigoids to increase the photochromatic response of thesystem.

In some embodiments, light-actuated SMP materials may be preferable tothermally-actuated materials. Any thermally-actuated SMP intended foruse in the body must necessarily have an actuation temperature at leastsomewhat above the normal human body temperature. Many activeingredients that may be placed into the consumable capsule for targeteddelivery may be sensitive to heat, which is more difficult to shieldfrom than is light. Optically-actuated SMP materials are contemplatedthat actuate at various wavelengths of light, from infrared throughultra-violet. This offers a further advantage that an LED with a highelectrical to light conversion efficiency may be used and the SMPmaterial may be designed around the wavelength produced by that LED. Inthis way, a high power conversion efficiency may be achieved in theconsumable capsule, lowering the necessary power input to the body. Insome embodiments, a bio-compatible organic LED may be used. For example,an organic LED using DNA as an electron-blocking layer may be used. Thistype of organic LED has a high luminous efficiency and total luminouspower. The wavelength at which such LEDs emit light may be tunable byadjusting the materials used to construct the LED.

Furthermore, in some embodiments, shape changing or smart polymers mayalso function as means to move the consumable capsule about within thebody. For example, the smart polymer may be shaped into “flagellum” or“fins” which may propel the consumable capsule via repetitive bending.The bending may be activated by repeated use LEDs emitting differentwavelengths of light.

With reference now to FIG. 11A, a partial cross-sectional viewillustrating an example of an embodiment of a consumable capsule 1100 isshown, in accordance with various aspects of the present disclosure.FIGS. 11B and 11C further illustrate sectional views of the consumablecapsule 900.

The consumable capsule 1100 includes orthogonal secondary coils 1105 andcontrol electronics 1110. The orthogonal secondary coils 1105 andcontrol electronics 1110 are enclosed within an electronics section1115. The consumable capsule 1100 also includes a compartment section1140 having a first delivery compartment 1120 and a second deliverycompartment 1125. The first delivery compartment is formed by a firstwall 1182 and a second wall 1184 of the compartment section 1140. Thefirst wall 1182 and the second wall 1184 are connected by a firstprimary support column 1152 (shown in FIGS. 11B and 11C) and a secondprimary support column 1162. A first flexible polymer chamber wall 1165seals the active ingredient within the first delivery compartment. Afirst rigid shell 1175 encircles a portion of the first deliverycompartment 1120 and first flexible polymer chamber wall 1165. Theportion of the first flexible polymer chamber wall 1165 not encircled bythe first rigid shell 1175 forms a first flexible polymer burst cover1185 (shown in FIGS. 12A-12C). A first thermally expansive material 1130fills the volume between the first flexible polymer chamber wall 1165and the first rigid shell 1175.

The second delivery compartment 1125 is formed by the second wall 1184and a third wall 1186 of the compartment section 1140. The first supportcolumn 1152 (shown in FIGS. 11B and 11C) and the second support column1162 further connect the second wall 1184 and the third wall 1186. Thesecond delivery compartment 1125 is sealed by a similar layeredstructure as the first delivery compartment 1120, including a secondflexible polymer chamber wall 1170, a second rigid shell 1180, and asecond thermally expansive material 1135 filling the volume between thesecond flexible polymer chamber wall 1170 and the second rigid shell1180. The portion of the second flexible polymer chamber wall 1170 notencircled by the second rigid shell 1180 forms a second flexible polymerburst cover 1190.

In some embodiments, the electronics section 1115 and the compartmentsection 1140 may be manufactured independently. The electronics section1115 may then be bonded to the first wall 1182 of the compartmentsection 1140 through various bonding techniques, such as sonic weldingor with an adhesive. The electronics section 1115 and the compartmentsection 1140 may be made from the same or different materials. Forexample, the electronics section 1115 may be made from an inert materialthat is not digestible (e.g., polyethylene), while the compartmentsection 940 may be made from a digestible material (e.g.,polylactic-co-glycolic acid (PLGA)).

In other embodiments, the electronics section 1115 and the compartmentsection 1140 may be manufactured as a single structure from the samematerial, either inert or digestible.

Each delivery compartment may include an active ingredient. Thecomponents of the consumable capsule 900 may further includebio-compatible components, as described in reference to FIGS. 7A-7C.While shown with two delivery compartments, one of ordinary skill wouldunderstand the consumable capsule 1100 may be configured with a singledelivery compartment, or three or more delivery compartments.

The orthogonal secondary coils 1105 include three coils arrangedorthogonally to one another, as described in reference to FIGS. 7A-7C.The energy received by each of the coils of the orthogonal secondarycoils 1105 may be used to provide power to the consumable capsule 1100.Control electronics 1110 may combine the energy received by each of thecoils and convert the total received energy into a power source, asdescribed in reference to FIGS. 6A-6B.

The control electronics 1110 trigger the release of the activeingredient in the first delivery compartment by heating the firstthermally expansive material 1130. The first thermally expansivematerial 1130 is heated when the control electronics 1110 apply anelectric current to the first thermally expansive material 1130.Alternatively, the control electronics 1110 may apply an electriccurrent to heating elements (not shown). The heating elements then heatthe first thermally expansive material 1130. The heating elements may beembedded within the first thermally expansive material 1130 or embeddedwithin the compartment section 1140. Alternatively, the heating elementsmay coat specific surfaces of the compartment section 1140 that are incontact with the first thermally expansive material 1130. For example,portions of the first and second support columns 1152 and 1162 and/orportions the first, second, and third walls 1182, 1184, and 1186 may becoated in a metallic material which acts as a heating element when anelectric current is applied by the control electronics 1110. Theelectric current is supplied to the first thermally expansive material1130 or heating elements via a first heater power line 1145 and a firstheater return line 1150 (shown in FIG. 11B).

When the first thermally expansive material is heated, it expands andpushes on the first flexible polymer chamber wall 1165. The pressureapplied by the thermally expansive material causes the portion of thefirst flexible polymer chamber wall 1165 not encircled by the firstrigid shell 1175 (i.e., the first flexible polymer burst cover 1185) torupture or open. The first flexible polymer burst cover 1185 may includescoring so that a specific portion of the first flexible polymer burstcover 1185 is more likely to rupture. The opened first flexible polymerburst cover 1185 allows the active ingredient in the first deliverycompartment 1120 to be released in the consumer's GI tract. The controlelectronics 1110 trigger the release of the active ingredient in thesecond delivery compartment 1125 in a similar way—by heating the secondthermally expansive material 1135 via a second heater power line 1155and a second heater return line 1160. The control electronics 1110 maybe configured to trigger the first and second delivery compartmentssequentially or simultaneously, as described above.

The thermally expansive materials may include medium length n-Alkaneparaffin waxes (e.g., n-Alkane paraffin wax having approximately 32Carbons in the polymer structure), or Calcium Carbonate Tetrahydrate(CaCl2-4H2O). These materials are bio-compatible and exhibit a volumeexpansion of at least 10% when melting from a solid to liquid phase.Additionally, these materials melt between 35 C and 70 C, which wouldallow them to remain solid prior to ingestion. Other non-toxic materialsexhibiting similar properties may also be used for the thermallyexpansive materials.

FIG. 12A illustrates a partial cross-sectional view of an example of anembodiment of a consumable capsule 1200, in accordance with variousaspects of the present disclosure. The consumable capsule 1200 is anexample of the consumable capsule 1100 shown in FIGS. 11A-11C after thedelivery compartments are opened. FIGS. 12B and 12C further illustratesectional views of the consumable capsule 1200.

As described with reference to FIG. 11A-11C, the control electronics1110 trigger the release of the active ingredient in the deliverycompartments 1120 and 1125 by heating the thermally expansive materials1130 and 1135, causing the material to expand. For example, the firstthermally expansive material 1130 expands and pushes on the firstflexible polymer chamber wall 1165. The pressure applied by the firstthermally expansive material 1130 causes the first flexible polymerburst cover 1185 to rupture or open, as shown in FIGS. 12A-12C. Theopened first flexible polymer burst cover 1185 allows the activeingredient in the first delivery compartment to be released in theconsumer's GI tract. The control electronics 1110 trigger the release ofthe active ingredient in the second delivery compartment in a similarway by rupturing the second flexible polymer burst cover 1190 with thepressure created by the expanded second thermally expansive material1135, as shown in FIGS. 12A-12C. While shown with two deliverycompartments, one of ordinary skill would understand the consumablecapsule 1200 may be configured with a single delivery compartment, orthree or more delivery compartments.

FIG. 13A illustrates a partially transparent view of an example of anembodiment of a consumable capsule 1300, in accordance with variousaspects of the present disclosure. FIG. 13B further illustrates asectional view of the consumable capsule 1300.

The consumable capsule 1300 includes similar components as theconsumable capsules described in reference to FIGS. 7A-12C. However, theconsumable capsule 1300 includes at least one delivery compartment 1320movably sealed by a stimuli responsive valve actuator 1330. The stimuliresponsive valve actuator 1330 changes shape in responsive to certainwavelengths of light emitted by LED 1340. The LED 1340 may be powered bycontrol electronics 1310 within an electronics section 1315 of theconsumable capsule 1300. The control electronics 1310 may distributepower to the LED 1340 and operate in a similar manner as described inreference to FIGS. 6C, 7D-7F, and 9D-9F.

The stimuli responsive valve actuator 1330 changes shape to allow anactive ingredient within the delivery compartment 1320 to be releasedthrough openings 1332, as further shown in FIGS. 14A and 14B. Whileshown with four openings 1332 in FIG. 13A, it should be understood thatthe consumable capsule 1300 may include fewer or more openings 1332. Inaddition, the consumable capsule 1300 may include additional deliverycompartments, each sealed by additional respective stimuli responsivevalve actuators. The additional stimuli responsive valve actuators mayeach be activated by additional respective LEDs, or by the LED 1340. Insome embodiments, the LED 1340 may include multiple LEDs capable ofemitting light at different wavelengths.

The stimuli responsive valve actuator 1330 operates in a similar manneras described in reference to FIGS. 7D-7F and 9D-9F. Overall, themolecules of the stimuli responsive valve actuator 1330 transform from astraight configuration (trans) to a bent configuration (cis) in responseto light emitted by the LED 1340, which is responsible for the shapechange of the actuator 1330, as shown in FIGS. 14A-14B. The stimuliresponsive valve actuator 1330 may include azo-LCE material that bendsafter exposure to 366 nm light and reverts completely to its initialstate after irradiating with natural light. The azo-LCE valve actuator1330 may be bent after exposure to 366 nm light with the intensity of2.0 mW/cm-2 for 10 to 35 seconds, as further described in reference toFIGS. 7D-7F.

FIG. 14A illustrates a partially transparent view of an example of anembodiment of a consumable capsule 1400, in accordance with variousaspects of the present disclosure. The consumable capsule 1400 is anexample of the consumable capsule 1300 shown in FIGS. 13A-13B after thedelivery compartment is opened. FIG. 14B further illustrates a sectionalview of the consumable capsule 1400.

As described with reference to FIG. 13A, the stimuli responsive valveactuator 1330 changes shape in response to certain wavelengths of lightemitted by LED 1340. As shown in FIG. 14A, the stimuli responsive valveactuator 1330 may deform or bend inwardly toward the center of thecapsule 1400. When in this bent shape, a channel is formed between thestimuli responsive valve actuator 1330 and the outer shell of theconsumable capsule 1400. This channel allows an active ingredient withinthe delivery compartment 1320 to be released through openings 1332. FIG.14B more clearly illustrates the channel between the stimuli responsivevalve actuator 1330 and the outer shell of the consumable capsule 1400.In some embodiments, the active ingredient may be pressurized within thedelivery compartment 1320 to encourage the active ingredient to flow outof the openings 1332. In some embodiments, the stimuli responsive valveactuator 1330 may return to its original shape (as shown in FIGS.13A-13B) by emitting another wavelength of light with the LED 1340. TheLED 1340 may include multiple LEDs capable of emitting light atdifferent wavelengths. While shown with four openings 1332 in FIG. 14A,it should be understood that the consumable capsule 1400 may includefewer or more openings 1332. In addition, the consumable capsule 1400may include additional delivery compartments, each sealed by additionalrespective stimuli responsive valve actuators. The additional stimuliresponsive valve actuators may each be activated by additionalrespective LEDs, or by the LED 1340.

In some embodiments, the consumable capsule is incorporated into a foodor beverage product, such that the consumable capsule is ingested byingesting the food or beverage into which the consumable capsule isincorporated. The food or beverage into which the consumable capsule isembedded is generally not limited. In some embodiments, the consumablecapsule is incorporated into a solid food, such as a bar, baked good, orgummy product. In some embodiments, the consumable capsule isincorporated into a yogurt, goo, shake or other viscous food product. Insome embodiments, the consumable capsule is incorporated into a liquid,such as juice, water, milk, or the like. The consumable capsule can alsobe provided in the form a single use packet that is mixed into abeverage, viscous food product, or solid food of the user's choice, suchas a bottle of water or a yogurt.

Any suitable method can be used for making the consumable capsulesdescribed herein. In some embodiments, the consumable capsule ismanufactured using traditional pharmaceutical methods for manufacturingtablets, capsules, pills, beads and the like. In such methods, theactive ingredients are mixed together with the binding agents to form aslurry, which is then dried in the desired shape. For the consumablecapsule described herein, the internal electronic components can beincluded with the active ingredients and whatever other components areused to form the consumable capsule product (e.g., binding agents). Anycoating layers can then be applied to the consumable capsule, such as byspray coating. In capsule manufacturing, the mixed material is placedinside a capsule which is then sealed together.

Other methods for manufacturing the consumable capsule are contemplated,such as 3D printing technology. 3D printing technology may be used tomanufacture one or more components of the capsule, including, forexample, the housing, electronic components, support structurecomponents, actuators, and/or active ingredients.

FIG. 15 is a flowchart illustrating an example of a set of operationsfor triggering the release of active ingredients, in accordance withvarious aspects of the present disclosure. The operations illustrated inFIG. 15 may be executed by an activation device, an externalcommunication device, and/or a combination of devices. The devices mayinclude a memory and one or more processors. These components areexamples of various means for performing some of the operationsillustrated in FIG. 15.

At block 1505, the set of operations include receiving a firstelectromagnetic signal by a consumable capsule. In some examples, thefirst electromagnetic signal may be generated by activation device, inresponse to a signal from an external communication device. At block1510, the set of operations include converting the first electromagneticsignal into a power source through inductive coupling. For example,coils within the consumable capsule may generate low level signals fromthe electromagnetic energy of the first electromagnetic signal. Theconsumable capsule may then convert the low-level signals into the powersource. At block 1515, the set of operations include releasing a firstactive ingredient from a first delivery compartment using the powersource. For example, the consumable capsule may provide power to anactuator, which changes shape to release the first active ingredient.

At block 1520, the set of operations include receiving a secondelectromagnetic signal by a consumable capsule. In some examples, thesecond electromagnetic signal may be generated by activation device, inresponse to a signal from an external communication device. At block1525, the set of operations include converting the first electromagneticsignal into a power source. For example, coils within the consumablecapsule may generate low-level signals from the electromagnetic energyof the second electromagnetic signal. The consumable capsule may thenconvert the low-level signals into the power source. At block 1530, theset of operations include releasing a second active ingredient from asecond delivery compartment using the power source. For example, theconsumable capsule may provide power to another actuator, which changesshape to release the second active ingredient. The first and secondactive ingredients may be the same or different active ingredients.

In some embodiments, the active ingredient in the second deliverycompartment may be released without receiving the second electromagneticsignal in block 1520. In these embodiments, the active ingredient in thesecond delivery compartment is released using the power supplied by thefirst electromagnetic signal in block 1510. The active ingredient may bereleased from the second delivery compartment at the same time as theactive ingredient in the first delivery compartment. Alternatively, theactive ingredient may be released from the second delivery compartmentat a predetermined time following the receipt of the firstelectromagnetic signal, or may be released based on other signals orconditions.

In some embodiments, after the release of the first and/or second activeingredient, the consumable capsule may generate a notification that theactive ingredient has been released. Alternatively, an activation deviceor external communication device may detect the active ingredient hasbeen released based on one or more characteristics of the consumablecapsule.

Embodiments of the present technology include various steps andoperations, which have been described above. A variety of these stepsand operations may be performed by hardware components or may beembodied in machine-executable instructions, which may be used to causea general-purpose or special-purpose processor programmed with theinstructions to perform the steps. Alternatively, the steps may beperformed by a combination of hardware, software, and/or firmware. Assuch, FIG. 16 is an example of an embodiment of a computer system 1600with which embodiments of the present technology may be utilized. Forexample, the external communication device or activation device mayinclude one or more aspects of the computer system 1600. According tothe present example, the computer system 1600 includes a bus 1610, atleast one processor 1620, at least one communication port 1630, mainmemory 1640, a removable storage media 1650, a read only memory 1660,and a mass storage 1670.

Processor(s) 1620 can be any known processor, such as, but not limitedto, Intel® lines of processor(s); AMD® lines of processor(s); ARM® linesof processors, or other application-specific integrated circuits(ASICs). Communication port(s) 1630 can be any communication port, suchas, but not limited to, an RS-232 port for use with a modem-based dialupconnection, a 10/100 Ethernet port, a Gigabit port using copper orfiber, wireless coils, etc. Communication port(s) 1630 may be chosendepending on a network such as a Local Area Network (LAN), Wide AreaNetwork (WAN), cellular network, Near Field Communication (NFC),Bluetooth, or any network on which the computer system 1600communicates.

Main memory 1640 can be Random Access Memory (RAM) or any other dynamicstorage device(s) commonly known in the art. Read only memory 1660 canbe any static storage device(s) such as Programmable Read Only Memory(PROM) chips for storing static information such as instructions forprocessor 1620.

Mass storage 1670 can be used to store information and instructions. Forexample, a solid state memory, a hard disk, an optical disc, an array ofdisks such as RAID, or any other mass storage devices may be used.

Bus 1610 communicatively couples processor(s) 1620 with the othermemory, storage and communication blocks. Bus 1610 can be any systemcommunication bus, such as, but limited to, I2C, PCI, PCI-Express, UMI,DMI, QPI, etc.

Removable storage media 1650 can be any kind removable storage, such as,but not limited to, external hard-drives, flash memory cards, floppydrives, Compact Disc-Read Only Memory (CD-ROM), Compact Disc-Re-Writable(CD-RW), Digital Video Disk-Read Only Memory (DVD-ROM), Blu-Ray, etc.

Various embodiments of the present disclosure relate to systems,methods, and apparatus for activating a consumable capsule. In oneexample implementation, a system for activating the consumable capsuleincludes a consumable capsule containing an active ingredient in atleast one compartment movably sealed by a stimuli responsive actuator;and an activation device configured to communicate with the consumablecapsule, wherein the activation device is configured to emit a wirelesssignal to activate the stimuli responsive actuator of the consumablecapsule, and wherein the consumable capsule is configured to release theactive ingredient into an external environment based on the activationof the stimuli responsive actuator.

In some examples, the system further includes a communication deviceconfigured to instruct the activation device to emit the wirelesssignal. In some examples, the communication device is configured toinstruct the activation device to emit the wireless signal based on userinput. In some examples, the communication device is configured toinstruct the activation device to emit the wireless signal based on atleast one physical attribute of a user. In some examples, thecommunication device is configured to instruct the activation device toemit the wireless signal based on at least one environmental attribute.In some examples, the stimuli responsive actuator comprises azobenzeneincorporated in a liquid-crystalline elastomer. In some examples, thestimuli responsive actuator is activatable based at least in part onlight emitted in response to the wireless signal. In some examples, thecommunication device and the activation device are in a common housing.In some examples, the consumable capsule comprises at least one coil forreceiving the wireless signal. In some examples, the consumable capsuleis powered by the wireless signal. In some examples, the activationdevice is a wearable item for encircling a user's abdomen. In someexamples, the activation device is configured to detect a release statusof the active ingredient. In some examples, the activation device isconfigured to provide an indication of a release status of the activeingredient. In some examples, said indication comprises one or more of avisual indication, an audible indication, and a tactile indication. Insome examples, said indication comprises an acknowledgement signaltransmittable to a communication device. In some examples, the activeingredient comprises one or more of stimulants, electrolytes, vitamins,minerals, nitroglycerin, and appetite suppressant.

In another example implementation, the consumable capsule includes asignal receiving section comprising at least one coil configured toreceive a wireless signal; a control section configured to condition thewireless signal received by the at least one coil into a trigger signalfor the consumable capsule; a compartment section comprising at leastone capsule compartment movably sealed by a stimuli responsive actuator,the compartment section being configured to activate the stimuliresponsive actuator in response to the trigger signal from the controlsection to allow for release of an active ingredient contained in the atleast one capsule compartment into an external environment.

In some examples, the at least one coil comprises three orthogonalcoils. In some examples, the stimuli responsive actuator comprisesazobenzene incorporated in a liquid-crystalline elastomer. In someexamples, the compartment section further comprises a light sourceconfigured to emit light based at least in part on the trigger signal,and wherein the stimuli responsive actuator is activated based at leastin part on the emitted light. In some examples, the compartment sectioncomprises at least two capsule compartments, the compartment sectionconfigured to release an active ingredient contained in the at least twocapsule compartments approximately simultaneously. In some examples, thecompartment section comprises a plurality of capsule compartments, thecompartment section being configured to sequentially open each capsulecompartment of the plurality of capsule compartments. In some examples,a first capsule compartment of the plurality of capsule compartments isopened based on the trigger signal, and a second capsule compartment ofthe plurality of capsule compartments is opened based on a secondarytrigger signal from the control section. In some examples, the secondarytrigger signal is transmittable by the control section in response to asecondary wireless signal received by the at least one coil. In someexamples, the secondary trigger signal is transmittable by thecontroller a predetermined time after the first capsule compartment isopened. In some examples, the predetermined time is user configurable.In some examples, the consumable capsule further includes a transmittersection configured to report a status of the consumable capsule to anexternal device that is indicative of an open state of at least onecapsule compartment. In some examples, the control section conditionsthe wireless signal into a direct current (DC) power source. In someexamples, the control section includes at least one rectifying circuitfor rectifying the wireless signal; and at least filtering circuit forfiltering the wireless signal. In some examples, the control sectionincludes at least one rectifying circuit for rectifying the wirelesssignal, the rectifying circuit comprising at least one light emittingdiode (LED), and wherein the at least one LED is configured to activatethe stimuli responsive actuator. In some examples, the trigger signalfrom the control section comprises a DC power signal.

In another example implementation, the consumable capsule includes ahousing comprising an outer shell; an electronics section within thehousing comprising control electronics and at least one coil; and acompartment section including a support structure connected to thehousing; a first wall and a second wall supported by the supportstructure to define at least one capsule compartment; at least onelinear stimuli responsive actuator movably sealing the at least onecapsule compartment, the at least one linear stimuli responsive actuatorbeing responsive to a trigger signal transmitted by the controlelectronics to unseal the at least one capsule compartment.

In some examples, the at least one linear stimuli responsive actuator isresponsive to the trigger signal to compress longitudinally and expandcircumferentially. In some examples, trigger signal is configured toapply an electric field to the at least one linear stimuli responsiveactuator. In some examples, the stimuli responsive actuator comprises atleast one of Polypyrrole, Polyaniline, Polythiopene, or a combinationthereof. In some examples, the support structure includes at least onerigid connection element embedded in the at least one linear stimuliresponsive actuator and connecting the first wall and the second wall.In some examples, the compartment section further includes a positivepower line and a negative power line connecting the at least one linearstimuli responsive actuator to the control electronics. In someexamples, the positive power line and the negative power line areembedded in the support structure.

In another example implementation, the consumable capsule includes ahousing comprising an outer shell; an electronics section within thehousing comprising control electronics and at least one coil; and acompartment section including a support structure connected to thehousing; a first wall and a second wall supported by the supportstructure to define at least one capsule compartment; at least onebendable, or otherwise deformable, stimuli responsive actuator movablysealing the at least one capsule compartment, the at least one bendingstimuli responsive actuator being responsive to a trigger signaltransmitted by the control electronics to unseal the at least onecapsule compartment.

In some examples, the at least one bending stimuli responsive actuatorcomprises a stimuli responsive layer connected to a substrate layer. Insome examples, the stimuli responsive layer is responsive to the triggersignal to decrease in volume and cause the at least one bending stimuliresponsive actuator to bend or otherwise deform outwardly from the atleast one capsule compartment. In some examples, the trigger signal isconfigured to apply an electric field to the stimuli responsive layer.In some examples, the stimuli responsive actuator comprises at least oneof Polypyrrole, Polyaniline, Polythiopene, or a combination thereof. Insome examples, the compartment section further includes a positive powerline and a negative power line connecting the at least one linearstimuli responsive actuator to the control electronics. In someexamples, the positive power line and the negative power line areembedded in the support structure.

In another example implementation, the consumable capsule includes ahousing comprising an outer shell; an electronics section within thehousing comprising control electronics and at least one coil; and acompartment section including a support structure connected to thehousing; a first wall and a second wall supported by the supportstructure to define a capsule compartment; a chamber wall lining thecapsule compartment; a rigid shell encircling a first portion of thechamber wall, wherein a second portion of the chamber wall not encircledby the rigid shell forms a burst cover; and a thermally expansivematerial filling a volume between the chamber wall and the rigid shell,the thermally expansive material being responsive to a trigger signaltransmitted by the control electronics to expand and cause the burstcover to rupture.

In some examples, the trigger signal is configured to heat the thermallyexpansive material by applying an electric current to the thermallyexpansive material. In some examples, the trigger signal is configuredto heat the thermally expansive material by applying an electric currentto one or more heating elements. In some examples, the one or moreheating elements are embedded in the support structure. In someexamples, the one or more heating elements are embedded in the thermallyexpansive material. In some examples, the thermally expansive materialcomprises at least one of paraffin wax, calcium carbonate tetrahydrate,or a combination thereof.

In another example implementation, an activation device includes anattachment mechanism configured to hold the activation device in closeproximity to a user's body; and a transmitter configured to emit awireless signal to a consumable capsule, wherein the wireless signal isconfigured to activate the consumable capsule, causing the consumablecapsule to release an active ingredient.

In some examples, the attachment mechanism comprises an adhesive. Insome examples, the attachment mechanism comprises a releasable band offabric. In some examples, the attachment mechanism is configured to holdthe activation device in proximity to the user's abdomen. In someexamples, the transmitter comprises a coil of litz wire. In someexamples, the transmitter is configured to emit the wireless signal inresponse to user input. In some examples, the transmitter is configuredto emit the wireless signal based on at least one physical attribute ofthe user. In some examples, the transmitter is configured to emit thewireless signal based on at least one environmental attribute. In someexamples, the transmitter is configured to emit the wireless signal inresponse to an instruction from a communication device. In someexamples, the activation device further includes a detector configuredto detect a release status of the active ingredient. In some examples,the detector is configured to receive a status signal from theconsumable capsule. In some examples, the detector is configured totrack a location of the consumable capsule. In some examples, theactivation device further includes a user interface configured toprovide an indication of the release status of the active ingredient. Insome examples, the indication comprises one or more of a visualindication, an audible indication, and a tactile indication. In someexamples, the transmitter is configured to transmit an acknowledgementsignal to a communication device.

In another example implementation, a method for activating a consumablecapsule includes receiving a wireless signal from an activation device;conditioning the wireless signal into a power signal; distributing thepower signal to an actuator; modifying a shape of the actuator inresponse to the power signal; and allowing an active ingredient to bereleased in response to the modified shape of the actuator.

In another example implementation, a method for activating a consumablecapsule includes transmitting a wireless signal to the consumablecapsule; receiving a release status of the consumable capsule; andindicating the release status to a user. In some examples, the methodincludes receiving an instruction from a communication device totransmit the wireless signal to the consumable capsule. In someexamples, indicating the release status comprises transmitting therelease status to the communication device.

In another example implementation, the consumable capsule includes ahousing comprising an outer shell; an electronics section within thehousing comprising control electronics and at least one coil; and acompartment section including at least one capsule compartment withinthe housing; at least one opening extending through the outer shell; atleast one light source configured to receive a signal from the controlelectronics and emit light comprising a first wavelength; and at leastone stimuli responsive valve actuator arranged between the at least oneopening and the at least one capsule compartment and movably sealing theat least one capsule compartment, the at least one stimuli responsivevalve actuator being responsive to the first wavelength of light emittedby the at least one light source to unseal the at least one capsulecompartment.

In some examples, the at least one stimuli responsive valve actuatorcomprises azobenzene incorporated in a liquid-crystalline elastomer. Insome examples, the at least one light source is configured to emit lightcomprising a second wavelength, and wherein the at least one stimuliresponsive valve actuator is responsive to the second wavelength oflight to reseal the at least one capsule compartment. In some examples,the control electronics comprises at least one rectifying circuit forrectifying a wireless signal received by the at least one coil, therectifying circuit comprising the at least one light source. In someexamples, at least one active ingredient is contained within the atleast one capsule compartment, the at least one active ingredientcomprising one or more of stimulants, electrolytes, vitamins, minerals,nitroglycerin, and appetite suppressant.

The components described above are meant to exemplify some types ofpossibilities. In no way should the aforementioned examples limit thescope of the technology, as they are only embodiments.

From the foregoing, it will be appreciated that specific embodiments ofthe invention have been described herein for purposes of illustration,but that various modifications may be made without deviating from thescope of the invention. Accordingly, the invention is not limited exceptas by the appended claims.

We claim:
 1. A system for activating a consumable capsule, comprising: aconsumable capsule containing an active ingredient in at least onecompartment movably sealed by a stimuli responsive actuator comprisingat least one stimuli responsive material; and an activation deviceconfigured to communicate with the consumable capsule, wherein theactivation device is configured to emit a wireless signal to activatethe stimuli responsive actuator of the consumable capsule, wherein theactivation device is configured to provide power to the consumablecapsule, and wherein the consumable capsule is configured to release theactive ingredient into an external environment based on the activationof the stimuli responsive actuator.
 2. The system of claim 1, furthercomprising: a communication device configured to instruct the activationdevice to emit the wireless signal.
 3. The system of claim 2, whereinthe communication device is configured to instruct the activation deviceto emit the wireless signal based on user input.
 4. The system of claim2, wherein the communication device is configured to instruct theactivation device to emit the wireless signal based on at least onephysical attribute of a user.
 5. The system of claim 2, wherein thecommunication device is configured to instruct the activation device toemit the wireless signal based on at least one environmental attribute.6. The system of claim 1, wherein the at least one stimuli responsivematerial comprises azobenzene incorporated in a liquid-crystallineelastomer.
 7. The system of claim 1, wherein the at least one stimuliresponsive material comprises an electro-active polymer.
 8. The systemof claim 1, wherein the stimuli responsive actuator is activatable basedat least in part on light emitted in response to the wireless signal. 9.The system of claim 1, wherein the activation device is configured to bewearable by the mammal that consumes the consumable capsule.
 10. Thesystem of claim 9, wherein the activation device is further configuredto monitor one or more aspects of the mammal's health.
 11. The system ofclaim 10, wherein the activation device emits the wireless signal toactivate the stimuli responsive actuator of the consumable capsule whenthe activation device monitoring one or more aspects of the mammal'shealth measures a condition in the mammal's health requiringadministration of the active ingredient.
 12. The system of claim 10,further comprising a communication device in wireless communication withthe activation device and the consumable capsule, wherein: theactivation device emits a wireless signal to the communication devicewhen the activation device monitoring one or more aspects of themammal's health measures a condition in the mammal's health requiringadministration of the active ingredient; and the communication deviceemits a wireless signal to activate the stimuli responsive actuator ofthe consumable capsule after a user reviews the wireless signal emittedby the activation device and received by the communication device andconfirms that the active ingredient should be administered to themammal.
 13. The system of claim 2, wherein the consumable capsule isconfigured to transmit a wireless signal to the activation device or thecommunication device when the stimuli responsive actuator has beenactivated.
 14. The system of claim 1, wherein the consumable capsule isa one-way communication device capable of only receiving a wirelesssignal.
 15. The system of claim 1, wherein the activation device isconfigured to emit the wireless signal based on user input.
 16. Thesystem of claim 1, wherein the activation device is configured to emitthe wireless signal based on at least one physical attribute of a user.17. The system of claim 1, wherein the activation device is configuredto emit the wireless signal based on at least one environmentalattribute.
 18. The system of claim 1, wherein the activation devicecomprises a primary coil and the consumable capsule comprises one ormore orthogonal secondary coils, wherein the primary coil is configuredto transmit an electromagnetic signal capable of inductively couplingwith the secondary coils to thereby allow the secondary coils togenerate a low-level AC signal capable of being used to supplying powerto the consumable capsule.
 19. The system of claim 1, wherein thestimuli responsive actuator is activatable based at least in part onheat emitted in response to the wireless signal.
 20. The system of claim1, wherein the stimuli responsive actuator is activatable based at leastin part on vibration emitted in response to the wireless signal.